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Abstract: Pancreatic adenocarcinoma is one of the most lethal cancers in both men and women, with a
median five-year survival of around 5%. Therefore, pancreatic adenocarcinoma represents an unmet
medical need. Neoplastic diseases, such as pancreatic adenocarcinoma, often are associated with
microbiome dysbiosis, termed oncobiosis. In pancreatic adenocarcinoma, the oral, duodenal, ductal,
and fecal microbiome become dysbiotic. Furthermore, the pancreas frequently becomes colonized (by
Helicobacter pylori and Malassezia, among others). The oncobiomes from long- and short-term survivors
of pancreatic adenocarcinoma are different and transplantation of the microbiome from long-term
survivors into animal models of pancreatic adenocarcinoma prolongs survival. The oncobiome
in pancreatic adenocarcinoma modulates the inflammatory processes that drive carcinogenesis.
In this review, we point out that bacterial metabolites (short chain fatty acids, secondary bile acids,
polyamines, indole-derivatives, etc.) also have a role in the microbiome-driven pathogenesis of
pancreatic adenocarcinoma. Finally, we show that bacterial metabolism and the bacterial metabolome
is largely dysregulated in pancreatic adenocarcinoma. The pathogenic role of additional metabolites
and metabolic pathways will be identified in the near future, widening the scope of this therapeutically
and diagnostically exploitable pathogenic pathway in pancreatic adenocarcinoma.
Keywords: pancreatic adenocarcinoma; oncobiome; microbiome; bile acids; bacterial metabolite;
amino acid metabolites; polyamines; LPS; short chain fatty acid
1. Pancreatic Adenocarcinoma, an Unmet Medical Need
Pancreatic adenocarcinoma stems from the exocrine glands and ducts of the pancreas and usually
appears in the head of the pancreas (2/3 of cases). Pancreatic adenocarcinoma is the fourth most
prevalent cancer with the highest mortality in both men and women [1]. Worldwide, in 2018, 458,918
cases were reported, and 432,242 deaths were estimated to be linked to pancreatic adenocarcinoma [2].
The number of pancreatic adenocarcinoma cases has continued to rise [3] and is predicted to rise even
more sharply in the future [4]. The five-year survival for pancreatic adenocarcinoma is around 5%,
as the disease progresses asymptomatically to the locally advanced or metastatic stages, reducing
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therapeutic effectiveness [1]. Thus, late diagnosis and a low five-year survival rate represent an unmet
medical need in pancreatic adenocarcinoma.
Curative surgical treatment can only be achieved in 15–20% of patients with pancreatic
adenocarcinoma, due to the spreading of the disease around blood vessels, rendering
patients inoperable. Neoadjuvant therapy can reduce tumor size and enable surgical excision.
The chemotherapy regimen to combat pancreatic adenocarcinoma includes nucleoside analogs
(gemcitabine, capecitabine), antimetabolites (5-fluorouracil), topoisomerase inhibitors (irinotecan),
taxanes (Nanoparticle albumin-bound (NAB)-paclitaxel), and platinum compounds (oxaliplatin) [5].
Combinatorial chemotherapies are organized into regimens known as FOLFIRINOX (Folinic
Acid-Fluorouracil-Irinotecan-Oxaliplatin) and FOLFOX (Folinic acid-Fluorouracil–Oxaliplatin) [5].
There are also new chemotherapy modalities on the way (e.g., Poly(ADP-ribose) polymerase (PARP)
inhibitors [6]). Chemotherapy can be complemented by radiotherapy; however, evidence supporting
the use of radiotherapy is very scarce. The treatment of pancreatic adenocarcinoma calls for a
multidisciplinary approach especially in patients undergoing neoadjuvant therapy [7].
Environmental risk factors for pancreatic adenocarcinoma include smoking, alcoholism, chronic
or recurrent pancreatitis, obesity, and diabetes mellitus [8]. Genetic mutations are also associated with
pancreatic adenocarcinoma [9]. Mutations in KRAS were identified in approximately 80% of pancreatic
adenocarcinoma cases [10]. Recent studies associated other mutations with pancreatic adenocarcinoma,
including BRCA1, TP53, and a set of other DNA repair factors [9].
2. The Oncobiotic Transformation of the Microbiome
The microbiome shows characteristic changes in neoplastic diseases; the transformed microbiome,
a characteristic of neoplasia, is termed the oncobiome [11–18]. Recent advances demonstrate that
the oncobiome has a pathogenic role in neoplasia. An intricate relationship develops between the
microbiome and the host, where the host can influence the composition and biomass of the microbiome
through its behavior, feeding, and immune system, while the microbiome impacts on the host through
secreting microbial metabolites, as well as serving as bait for the immune system [19–30].
Hanahan and Weinberg [31,32] coined the term “cancer hallmark”, which refers to a collection
of biological processes that drive oncogenesis and support the unlimited proliferation of cancer cells.
The oncobiome plays either a direct or tangential role in regulating all cancer hallmarks. The oncobiome
is definitively involved in avoiding immune destruction, enhancing tumor promoting inflammation,
activating movement, invasion, and metastasis, inducing angiogenesis, inducing genome instability
and mutations, and deregulating cellular energetics [21–24,26–30,33–35].
Sustained inflammation and the consequent oxidative stress can lead to DNA damage and genomic
instability, which are risk factors for accumulating mutations and, subsequently, for carcinogenic
transformation [36–38]. A dysbiotic microbiome can drive local inflammation and, therefore, can be a
driver of carcinogenesis, including pancreatic adenocarcinoma [39–43]. In contrast, increased oxidative
stress can be cytostatic in certain malignancies, such as breast cancer [34,38]. In other words, oxidative
stress, induced by oncobiosis, can induce malignancies, but in later stages can have cytostatic properties.
The oncobiome usually has a different immunogenic character than the normal microbiome
(eubiome), as oncobiosis alters the immune system [21]. The tolerogenic character of the immune
system inhibits the early elimination of cancer cells [21]. A more immunogenic microbiome supports
immunotherapy/targeted therapy [27,44], while sustained, high-level inflammation can promote
carcinogenesis [24,39–43]. In this process, the actual physical presence of the bacteria seems to be a key
factor, but immunomodulatory bacterial metabolites are also important [23].
Several studies have shown that oncobiotic transformation supports cellular proliferation, invasion,
and metastasis [22–25]. In addition, oncobiosis changes the expression of vascular-endothelial growth
factor (VEGF) [23], implying that oncobiosis is involved in the regulation of tumor vascularization.
To date, published studies show that these processes are the main targets of oncobiosis and oncobiotic
bacterial metabolites.
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What are the elementary steps behind these processes? Bacterial metabolites modulate the redox
balance of cancer cells [24,34], as well as cancer cell metabolism [22,23]. These processes culminate
in cytostasis, a reprogramming of the epithelial-mesenchymal transition leading to decreased cancer
stem cells [22–25,29,34,35,45]. These basic events are the pillars for the inhibition of cancer cell growth,
movement, and metastasis formation [46–48].
What can cause oncobiotic transformation or, in general, changes to the microbiome? Among
the factors inducing oncobiosis, lifestyle plays a key role, including activities such as smoking [49],
diet, obesity [50], changes to the diurnal rhythm [51–53], aging [54–56], underlying diseases such
as diabetes [57], and exercise [58]. In fact, these factors are all individual risk factors for pancreatic
adenocarcinoma. In cancers, other than pancreatic adenocarcinoma, antibiotic [59] and probiotic
use [60,61] are also associated with carcinogenesis.
3. The Oncobiome in Pancreatic Adenocarcinoma
The relationship between the microbiome and pancreatic adenocarcinoma was first suggested
by the discovery that Helicobacter pylori colonization was associated with pancreatitis [62]. This was
followed by the discovery of associations between the oral [63], gut [64], pancreas [41,65,66],
and fecal [43,67] microbiomes, the mycobiome [68], and pancreatic cancer. Since then, there has
been an immense expansion of oncobiome studies focused on pancreatic adenocarcinoma.
According to our current understanding, elements of the oral, gastric, and intestinal microbiome
can drive inflammation, which is a risk factor for carcinogenesis in the pancreas. In brief, the oral, gastric,
and duodenal flora can colonize the common duct, the bile duct, and the pancreatic duct and, finally, the
pancreas itself, as shown in a series of animal and human studies [39,64,66,69–80]. Characteristic changes
occur to the oral [63,81–88] and duodenal microbiome [64] in pancreatic adenocarcinoma. Enterobacter,
Enterococcus, and E. coli bactibilia [78] or the colonization of the pancreas [41,65,68,89–94] are risk factors
for pancreatic adenocarcinoma. Of note, an oncogenic role of hepatotropic viruses (Hepatitis B and C
virus and Transfusion Transmitted/Torque Teno virus) in pancreatic adenocarcinoma has been observed
in a clinical setting, although the exact molecular mechanisms are yet unknown [78]. Similarly, changes to
the mycobiome were also reported in pancreatic adenocarcinoma [68]. In a murine genetic model (Kras−/−
Tp53−/− model), the food microbiome can also invade the pancreas [41]. The pathogenic role of bacterial
invasion in the pancreas was demonstrated by the decreased incidence of pancreatic adenocarcinoma
in gnotobiotic or antibiotic-treated mice [65]. Similar issues were raised in conjunction with human
premedication before surgery in pancreatic carcinoma patients [92]. There seems to be a specificity
among the antibiotics. For instance, penicillin increased the risk for pancreatic adenocarcinoma [95],
while broad range antibiotic cocktails (streptomycin, gentamicin, bacitracin, and ciprofloxacin [65] or
ampicillin, vancomycin, neomycin, and metronidazole [96]) were protective in murine models [97].
Furthermore, fecal microbiome transplantation modulates susceptibility to the disease [41,91].
The main findings concerning the oncobiome in pancreatic adenocarcinoma are summarized
in Table 1. There is no consensus on how the diversity of the microbiome changes in pancreatic
adenocarcinoma. The alpha diversity (Shannon index) of the tongue microbiome increases [86].
In contrast, the saliva microbiome showed no change in alpha diversity, while beta diversity was different
between cases and controls [88]. There was a tendency towards a lower alpha index (Operational
taxonomic unit (OTU) diversity) in the duodenum of pancreatic adenocarcinoma patients [64]. The alpha
diversity (Chao1, Shannon) of the pancreatic microbiome differed between cases and controls, but the
change was not consequent in the study of Pushalkar et al. [41] (also similar to the findings of [87]
and [65]). The pancreatic mycobiome alpha diversity (OTU, Shannon) decreased [68] in pancreatic
adenocarcinoma patients. Nevertheless, alpha diversity indices in patients with long-term survival
were higher than short-term survival [91]. The alpha diversity of the stool microbiome in patients with
adenocarcinoma was lower in two studies [43,94]. (For the explanation of the diversity indices we
refer the reader to the following references [98,99]).
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Table 1. The main findings of the human oncobiome studies in pancreatic adenocarcinoma.
Sample Type and Sample Size Method Changes to Microbiome Other Observations Ref.
Changes to the oral microbiome
11,328 individuals in a prospective study. Dental
health was monitored between 1971–1992
Periodontitis increases the risk for pancreatic
adenocarcinoma. [81]
10 resectable patients with pancreatic cancer and
10 matched healthy controls for oral microbiome
assay, 28 resectable pancreatic cancer, 28 matched
healthy controls, and 27 chronic pancreatitis
samples for validation
HOMIM hybridization array
Streptococci, Veilonella, Actinobacteria,
Campylobacter, and Prevotella increased in
pancreatic adenocarcinoma patients.
Neisseria elongata and Streptococcus mitis were
validated as biomarkers for pancreatic
adenocarcinoma.
[63]
Pre-diagnosis blood samples from 405 pancreatic
cancer cases and 416 matched controls, collected as
part of the European Prospective Investigation into
Cancer and Nutrition study
High serum antibodies against Porphyromonas
gingivalis ATTC 53978 showed a two fold increase
in risk for pancreatic adenocarcinoma. Those
individuals who had high antibody titer against
the commensal flora had a lower risk for
pancreatic adenocarcinoma as compared to those
with low titer.
[82]
8 pancreatic adenocarcinoma patients and 22
healthy controls
16S rDNA was amplified and
sequenced
The pancreatic cancer group had higher levels
of Leptotrichia, and lower levels of
Porphyromonas, and Neisseria. No difference in
diversity. Leptotrichia to Porphyromonas ratio
was significantly higher in pancreatic
adenocarcinoma patients.
[83]
Among 149 orodigestive cancers 6 pancreatic
adenocarcinoma cases
Treponema denticola chymotrypsin-like proteinase
that can induce matrix metalloproteinases, was
found in pancreatic adenocarcinoma using
immunohistochemistry.
[84]
361 incident pancreatic adenocarcinoma patients
and 371 matched controls from two prospective
cohort studies, the American Cancer Society
Cancer Prevention Study II and the National
Cancer Institute Prostate, Lung, Colorectal and
Ovarian Cancer Screening Trial.
DNA was isolated from oral
wash samples; 16S rRNA gene
V3-V4 was amplified and
sequenced using Roche 454 FLX
Titanium Pyrosequencing
system
Carriage of Porphyromonas gingivalis and
Aggregatibacter actinomycetemcomitans were
associated with a higher risk for pancreatic
adenocarcinoma. Fusobacteria and its genus,
Leptotrichia decreased the risk of pancreatic
adenocarcinoma. The genus Alloprevotella
increased the risk for pancreatic
adenocarcinoma.
[85]
30 stage I pancreas head adenocarcinoma patients
and 25 healthy controls
Tongue scrapes were collected
and the V3-V4 16S rDNA was
amplified and sequenced
Leptotrichia, Fusobacterium, Rothia, Actinomyces,
Corynebacterium, Atopobium, Peptostreptococcus,
Catonella, Oribacterium, Filifactor, Campylobacter,
Moraxella, and Tannerella were overrepresented,
while Haemophilus, Porphyromonas, and
Paraprevotella were underrepresented in
pancreatic adenocarcinoma patients.
Haemophilus, Porphyromonas, Leptotrichia, and
Fusobacterium distinguished pancreatic
adenocarcinoma patients from healthy subjects.
[86]
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Table 1. Cont.
Sample Type and Sample Size Method Changes to Microbiome Other Observations Ref.
Saliva samples from 280 pancreatic
adenocarcinoma cases (29 stage I, 160 stage II, 37
stage III, and 54 stage IV pancreatic tumors) of
which 273 was used in the study and 285 controls
V4 region of the 16S rRNA gene
was PCR amplified and
sequencing was performed on
the Illumina MiSeq.
Haemophilus genus showed a marginal
association with pancreatic cancer risk.
Enterobacteriaceae, Lachnospiraceae,
Bacteroidaceae, and Staphylococcaceae showed a
positive correlation with pancreatic cancer risk.
[88]
Helicobacter pylori colonization (seropositivity)
Cases with pancreatic cancer (n = 87) were
matched to controls (n = 263) using age, sex and
time for baseline investigation as
matching variables
H. pylori serology was analyzed
in stored serum samples using
an enzyme-linked
immunosorbent assay
H. pylori seropositivity was not associated with
pancreatic cancer in the total cohort (adjusted OR
1.25 (0.75–2.09)). However, a statistically
significant association was found in never smokers
(OR 3.81 (1.06–13.63) adjusted for alcohol
consumption) and a borderline statistically
significant association was found in subjects with
low alcohol consumption (OR 2.13 (0.97–4.69)
adjusted for smoking).
[62]
110 patients with pancreatic cancer
A polypeptide antibody against
the plasminogen-binding
protein (PBP) of Helicobacter
pylori and with the
ubiquitin-protein ligase E3
component, n-recognin 2
(UBR2), an enzyme highly
expressed in acinar cells of the
pancreas
The antibody was positive in 5 of 110 patients with
pancreatic cancer (5%). [69]
Venipuncture specimens were obtained from a
representative sample of 761 case patients and 794
randomly selected control subjects matched by
category of age and gender
Antibody seropositivity for H.
pylori and its virulence protein
CagA were determined by
commercial enzyme-linked
immunosorbent IgG assays
Compared with individuals seronegative for both
H. pylori and CagA, decreased pancreas-cancer risk
was seen for CagA seropositivity [adjusted OR,
0.68; 95% confidence interval (CI), 0.54–0.84],
whereas some increased risk was suggested for
CagA-negative H. pylori seropositivity (OR, 1.28;
95% CI, 0.76–2.13).
[70]
Changes to the duodenal microbiome
14 patients with pancreatic head cancer and 14
healthy controls.
Endoscopic duodenal mucosal biopsies
16S rRNA gene pyrosequencing
after the PCR amplification of
the V3-V4 region. The
rarefaction curves did not
approach a plateau.
Acinetobacter, Aquabacterium, Oceanobacillus,
Rahnella, Massilia, Delftia, Deinococcus, and
Sphingobium were more abundant in the
duodenal mucosa of pancreatic cancer patients,
whereas the duodenal microbiomes of healthy
controls were enriched with Porphyromonas,
Paenibacillus, Enhydrobacter, Escherichia, Shigella,
and Pseudomonas. Alpha and beta diversity
were not different between the two groups.
Pancreatic adenocarcinoma patients have a higher
incidence of H. pylori colonization. [64]
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Table 1. Cont.
Sample Type and Sample Size Method Changes to Microbiome Other Observations Ref.
Changes to the pancreatic microbiome
283 patients with pancreatic ductal
adenocarcinoma (PDAC)
Genomic DNA extracted from
FFPE tissue specimens assessed
using TaqMan primer/probe sets
to detect Fusobacterium species
8.8% detection rate of Fusobacterium species in
pancreatic cancers; however, tumor Fusobacterium
status was not associated with any clinical and
molecular features. In multivariate Cox regression
analysis, compared with the Fusobacterium
species-negative group, higher cancer-specific
mortality rates were observed in the Fusobacterium
positive group.
[89]
Human FFPE pancreatic adenocarcinoma samples
(n = 27)
Illumina sequencing of V1-V3
hypervariable regions of 16S
RNA gene.
Differential presence of Acinetobacter, Afipia,
Corynebacterium, Deltia, Enterobacter,
Enterococcus, Escherichia, Klebsiella,
Propionibacterium, Pseudomonas, Rastoria,
Sphingomonas, Staphylococcus, and Streptococcus
between healthy, pancreatitis, and pancreatic
adenocarcinoma tissues.
In the pancreas, the microbiome could not
discriminate between healthy, pancreatitis, and
pancreatic adenocarcinoma states.
Culturable bacteria are present in the human
pancreas with a mean of ~1 × 105 (aerobic) and
~1 × 105 (anaerobic) cfu/g of tissue after 48 h
of culture.
[65]
Pancreatic juice from pancreatic cancer (n = 20) and
duodenal cancer/bile duct cancer (n = 16) patients
PCR identification of bacterial
species by 16S ribosomal
RNA gene.
Enterococcus faecalis may be involved in
pancreas carcinogenesis.
E. faecalis is present in pancreas tissue in cancer
patients. Antibodies against E. faecalis capsular
polysaccharide is elevated in chronic
pancreatitis patients.
[90]
Patients with pancreatic adenocarcinoma (n = 32),
matched healthy individuals (n = 31).
stool and pancreas tissue were assessed
Sequencing of the V3-V4
hypervariable region of the 16S
RNA gene after PCR
amplification
Proteobacteria are more abundant in patients
with pancreatic adenocarcinoma as compared
to gut cancer patients.
[41]
105 subjects were enrolled of which 27 had
pancreatic adenocarcinoma, 57 had intraductal
papillary mucinous neoplasms and 21 had
benign lesions
Pancreas cyst fluid was
collected, total bacterial 16S
copy number was assessed, and
16S DNA was sequenced
Fusobacterium nucleatum and Granulicatella
adiacens were associated with high-grade
dysplasia. In network analysis, the network’s
nodes were Actinobacteria (Cutibacterium acnes),
Bacteroidetes, Firmicutes (Streptococcus anginous,
Granulicatella adiacens), and Proteobacteria
(Klebsiella aerogenes).
The number of 16S reads increases in precancerous
and cancer cases. [87]
Human fecal samples and specimens of pancreatic
tissue were collected under sterile conditions from
healthy volunteers and patients undergoing
surgery for PDA or pancreatic endocrine tumors
(benign disease)
PCR amplification and
sequencing of the ITS1 region of
the 18S rRNA gene using
Illumina sequencing
Pancreatic adenocarcinoma tumors with fungal
infiltration were enriched for Malassezia spp.
Ligation of mannose-binding lectin (MBL), which
binds to glycans of the fungal wall to activate the
complement cascade, was required for
oncogenic progression.
[68]
Long-term surviving (n = 22) and short-term
surviving (n = 21) pancreatic
adenocarcinoma patients.
From the tumor and feces 16S
rDNA V4 region was amplified
by PCR and sequenced in the
MiSeq platform (Illumina).
Intratumoral microbiome signature
(Pseudoxanthomonas-Streptomyces-
Saccharopolyspora-Bacillus clausii) is highly
predictive of long-term survivorship.
The microbiome that provides long-term survival
can be transplanted. [91]
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Table 1. Cont.
Sample Type and Sample Size Method Changes to Microbiome Other Observations Ref.
50 patients with pancreatic adenocarcinoma were
enrolled. In cases where a biliary stent was
inserted prior to surgery, the stent was removed
and cultured. In other cases, swabs of bile or
pancreatic fluid and tissue from the bile duct or
pancreas were obtained and cultured.
Classical culture
96% of the specimens demonstrated the
presence of microbes, 90% of all cases were
polymicrobial. The most frequent species
found were Enterobacteriaceae, Enterococcus
species, Candida species, and
Streptococcus milleri
[92]
152 Italian patients of which 72 had pancreas head
adenocarcinoma patients were present Classical culture
The most common bacteria among pancreas
head adenocarcinoma patients were E. coli, K.
pneumoniae, and P. aeruginosa, and less
frequently, Alcaligenes spp., Serratia spp., and
Enterococcus spp.
Although pancreas head carcinoma patients were
not assessed separately, only such patients were
present in the shortest survival cohort enabling the
assessment of that patient population. E. coli, K.
pneumoniae, and P. aeruginosa showed a high
percentage of resistance to third-generation
cephalosporins (3GCs), aminoglycosides class, and
quinolone group, especially to levofloxacin, but
the same bacteria were sensitive to carbapenems.
[93]
50 patients with pancreatic adenocarcinoma, 34
other organs (i.e., controls). In total, 189 tissue
samples (pancreatic duct, duodenum, pancreas),
57 swabs (bile duct, jejunum, stomach), and 12
stool samples.
The 16S rRNA V3–V4
hypervariable regions were
amplified using Illumina MiSeq
Lactobacillus ssp. was significantly higher in
noncancer subjects compared with cancer
subjects and the relative abundance of
Fusobacterium spp was higher in cancer subjects
compared with noncancer subjects.
[94]
Changes to stool microbiome
Prospective study, 85 pancreatic cancer (PC) and 57
matched healthy controls (HC) MiSeq sequencing
Phylum Bacteroidetes was significantly
increased, while Firmicutes and Proteobacteria
were decreased in PC patients versus
healthy controls.
Gut microbial diversity decreased in pancreatic
adenocarcinoma. Alpha diversity decreased. The
abundance of certain pathogens and
lipopolysaccharides-producing bacteria increased.
Probiotics and butyrate-producing bacteria
decreased. Changes to the microbiome can be used
as markers to detect pancreatic adenocarcinoma
and the obstructive and non-obstructive forms.
[43]
Patients with pancreatic adenocarcinoma (n = 32),
and matched healthy individuals (n = 31).
stool and pancreatic tissue were assessed
Sequencing of the V3-V4
hypervariable region of the 16S
RNA gene after PCR
amplification
Proteobacteria are more abundant in patients
with pancreatic adenocarcinoma as compared
to healthy controls.
[41]
Long-term surviving (n = 22) and short-term
surviving (n = 21) patients. Sequencing of
intratumor and stool microbiomes.
16S rDNA V4 region was
amplified by PCR and
sequenced in the MiSeq
platform (Illumina).
Intra-tumoral microbiome signature occurs in
pancreatic adenocarcinoma patients
(Pseudoxanthomonas-Streptomyces-
Saccharopolyspora-Bacillus clausii) that is highly
predictive of long-term survivorship.
The microbiome that provides long-term survival
can be transplanted. [91]
30 patients with pancreatic adenocarcinoma, 6
patients with pre-cancerous lesions, 13 healthy
subjects, and 16 with non-alcoholic fatty
liver disease
16S RNA was PCR amplified
and was sequenced using the
Illumina MiSeq platform and
LEfSe linear discriminant
analysis (LDA) was performed
Patterns of the microbiome can separate pancreatic
adenocarcinoma patients from healthy subjects
and patients with comorbidities (NAFLD, etc.)
and can discriminate between the etiology of
pancreatic adenocarcinoma.
[100]
Cancers 2020, 12, 1068 8 of 27
Some bacterial species showed a strong association with pancreatic adenocarcinoma. In the
oral microbiome, Porphyromonas gingivalis increased in pancreatic adenocarcinoma [64,82,83,85,101].
Helicobacter pylori [62,69,70], Enterobacter, Enterococcus [64,90,92,93], Fusobacteria [89,94,102],
and E. coli [64,93] were also shown to increase in pancreatic adenocarcinoma patients in multiple
studies. In a study assessing intratumor DNA and serum cell-free DNA (1000+ patients), Fusobacteria
count in tumors was higher compared to the healthy, untransformed tissues [102]. Fungal species, like
Malassezia, also increased in pancreatic adenocarcinoma patients [68]. The oral microbiome can be
used for diagnosis [63]. In fact, different risk factors of pancreatic adenocarcinoma are associated with
changes to the microbiome, including smoking [103], poor oral health or tooth loss [78], or recurrent
pancreatitis. There is a lower bacterial load in pancreatitis than in pancreatic adenocarcinoma.
Pancreatic bacterial invasion predominantly induces persistent inflammation. Both the innate and
adaptive immunity participate in recognizing pancreatic bacteria and orchestrating the subsequent
inflammatory reaction [39,40]. The involvement of Th1, Th2, and Th17 responses have all been
demonstrated [41,42]. In pancreatic adenocarcinoma, the proportions of LPS-producing bacteria
(e.g., Prevotella, Hallella, and Enterobacter [43]) increase. Lipopolysaccharide (LPS) can bind to the
Toll-like (TLR) receptors; TLR2, TLR4, and TLR9 are associated with pancreatic adenocarcinoma
development [104]. TLR activation induces the STAT3 and NF-κB pathways, which act as tumorigenic
factors increasing cellular proliferation and suppressing apoptosis [39].
Besides the direct immunogenicity of the microbiome, an endocrine-like function was also
described in several cancers [30,105–107] including pancreatic adenocarcinoma. Bacteria can produce
bacterial metabolites that enter the systemic circulation and act on distant cancer cells. This process
possesses features of endocrine signaling: a chemical entity is synthesized at one location, then
transferred to another anatomical site where it binds to receptors and exerts biological responses
there. Hereby, we will review the bacterial metabolites with possible pro- or anti-neoplastic features in
pancreatic adenocarcinoma.
4. Bacterial Metabolites Playing Role in Pancreatic Adenocarcinoma
The gut microbiome harbors a large number of species with an immense and diverse metabolism.
Bacterial metabolites or components of bacteria can enter the systemic circulation of the host and be
transferred to distant sites where the metabolites can exert hormone-like effects [19,30,108]. Bacterial
metabolism is largely dysregulated in pancreatic adenocarcinoma [43]. Below, we will review the
source and (possible) roles of pro- or anti-carcinogenic bacterial metabolites (Figure 1).
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Figure 1. Kno n bacterial metabolite-elicited signaling pathways in pancreatic adenocarcinoma.
Pro-proliferative metabolites are shown in red; antiproliferative me abolite are shown i green.
Abbreviat ons: SCFA—sho f ty acid, DCA—deoxycholic acid, LPS—lipopolysaccharide,
FFAR—free fatty acid rec ptor, TGR5—Takeda G Protein- l ceptor 5/ G-protein-coupled bile
acid receptor, EGFR—Epidermal growth factor receptor, TLR—Toll-like receptor, MAPK—mitogen
activated protein kinase, STAT—Signal transducer and activator of transcription.
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4.1. Short Chain Fatty Acids (SFCA)
Short chain fatty acids (SCFAs), namely acetate, propionate, butyrate, and lactate, are derived
from non-digestible carbohydrates by bacterial saccharolytic fermentation [109,110]. The major SCFAs
are acetate, propionate, and butyrate [111]. A smaller quantity of SCFA can be formed by amino
acid deamination; this is the only source of branched-chain short chain fatty acids [110]. Hydrolysis,
glycolysis, and the pentose-phosphate pathways are the key pathways for SCFA production [111],
nevertheless, other pathways are also active. SCFAs are produced in the colon. SCFA production affects
the pH of the colon and, hence, modulates the composition of the microbiome in the colon. SCFAs
can reduce the proliferation of Enterobacteriaceae (e.g., E. coli, Salmonella ssp., or Clostridia ssp.) and
Borrelia burgdorferi [112–115]. Furthermore, SCFAs can modulate the composition of the gut microbiome
through the direct modulation of the immune system [116].
SCFA production is common among bacteria. Bacteroidetes primarily produce acetate and
propionate, while Firmicutes chiefly produce butyrate [117]. Akkermansia muciniphila has a pivotal
role in propionate synthesis through the degradation of mucin [118]. Lachnospiraceae, Ruminococcus
obeum, and Roseburia inulinivorans produce propionate through the degradation of deoxy sugars (e.g.,
fucose, rhamnose), while Bacteroidetes and Negativicutes use hexoses to produce propionate [119].
Other propionate producers are Phascolarctobacterium spp., Dialister spp., Veillonella spp., Salmonella spp.,
Megasphaera elsdenii, and Coprococcus catus [120,121]. Acetate is predominantly produced by
Lactobacillus spp., Bifidobacterium spp., Akkermansia muciniphila, Bacteroides spp., Prevotella spp.,
Ruminococcus spp., and Streptococcus spp [108]. The bulk of butyrate production can be linked
to Odoribacter, Anaeotruncus, Faecalibacterium prausnitzii, Eubacterium rectale, Roseburia faecis, Clostridium
leptum, Coprococcus eutactus, Faecalibacterium prausnitzii, Eubacterium rectale, Anaerostipes caccae,
Eubacterium hallii, and an unnamed cultured species SS2/1 [120–123]. The bacterial species that
produce bacterial metabolites are summarized in Table 2.
Table 2. The microbial source of the metabolites mentioned in the review.
Parent Metabolite Bioactive Metabolite Genus Species Reference
complex
carbohydrates
simple
carbohydrates
mucin
acetate
Lactobacillus [108]
Bifidobacterium [108]
Bacteroides [108]
Prevotella [108]
Ruminococcus [108]
Streptococcus [108]
propionate
Lachnospiraceae [119]
Bacteroidetes [119]
Negativicutes [119]
Phascolarctobacterium [120,121]
Dialister [120,121]
Veillonella [120,121]
Salmonella [120,121]
Megasphaera elsdenii [120,121]
Coprococcus catus [120,121]
Akkermansia muciniphila [118]
Ruminococcus obeum [119]
Roseburia inulinivorans [119]
butyrate
Odoribacter [120–123]
Anaeotruncus [120–123]
Faecalibacterium prausnitzii [120–123]
Eubacterium rectale [120–123]
Roseburia faecis [120–123]
Clostridium leptum [120–123]
Coprococcus eutactus [120–123]
Faecalibacterium prausnitzii [120–123]
Eubacterium rectale [120–123]
Anaerostipes caccae [120–123]
Eubacterium hallii [120–123]
unnamed cultured species SS2/1 [120–123]
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Table 2. Cont.
Parent Metabolite Bioactive Metabolite Genus Species Reference
primary bile acids secondary bile acids
Clostridium [124–129]
Lactobacillus [124–129]
Bifidobacterium [124–129]
Eubacterium [124–126,128]
Ruminococcus [124–126,128]
Escherichia [124–126,128]
Bacteroides fragilis [124–129]
Bacteroides vulgatus [124–129]
Listeria monocytogenes [124–129]
polyamines
E. coli [108,130,131]
Enterococcus faecalis [108,130,131]
Staphylococcus aureus [108,130,131]
Haemophilus influenzae [108,130,131]
Neisseria flava [108,130,131]
Pseudomonas aeruginosa [108,130,131]
Campylobacter jejuni [108,130,131]
Yersinia pestis [108,130,131]
Vibrio cholerae [108,130,131]
Bacteroides dorei [108,130,131]
Bacteroides thetaiotaomicron [108,130,131]
Bacteroides fragilis [108,130,131]
Bacillus subtilis [108,130,131]
Proteus mirabilis [108,130,131]
lysine cadaverine
Streptococcus [132]
Shigella flexneri [132]
Shigella sonnei [132]
Escherichia coli [132]
tryptophan
tryptamine Clostridium sporogenes [133]
Ruminococcus gnavus [133]
indole acetic acid
Lactobacillus [133]
Clostridium [133]
Bacteroides [133]
The human serum reference concentrations of SCFAs fall into the range of 10–100 µM [134–136].
However, local concentrations can be as high as 1 mM [137]. SCFAs primarily bind to the free fatty
acid receptors (FFARs) found on both cancer cells and stromal cells [120,121,138,139]. SCFAs can be
utilized as an energy source by cells [108] and SCFAs can modulate epigenetics through inhibiting
histone deacetylases [140–142]. The activation of SCFA receptors controls numerous cancer hallmarks,
including cell proliferation, apoptosis, cell invasion, gene expression, metabolism, and immune
processes [140–144].
Acetate can ameliorate pancreatitis and its sequels, and, hence, protect against a risk factor of
pancreatic adenocarcinoma [145]. Acetate drives the epigenetic reprogramming of mesenchymal stem
cells towards cancer-associated fibroblasts that enhance the invasiveness of pancreatic adenocarcinoma
cells [146]. Butyrate, at a 2 mM concentration, can reduce the proliferation of cultured pancreatic
adenocarcinoma cells (Panc-1 and HPAF cells) and induce differentiation towards a secretory phenotype
marked by ultrastructural changes [147]. Furthermore, a hyaluronic acid conjugate of butyrate
proved to be cytostatic in a cultured pancreatic adenocarcinoma cell line [148]. Valproic acid,
a branched chain synthetic SCFA, was also cytostatic in pancreatic adenocarcinoma cells when
given in combination with 5-fluorouracil, suggesting similar properties for bacterial SCFAs [149].
In the pancreatic adenocarcinoma-associated oncobiome, probiotics and butyrate-producing bacteria
decreased [43], suggesting that the above-detailed beneficial effects of SCFAs are largely suppressed in
the disease.
4.2. Secondary Bile Acids
Chenodeoxycholic acid (CDCA) and cholic acid (CA) are primary bile acids, which are mainly
synthesized in the liver; however, extrahepatic tissues (e.g., ovaries, macrophages, vascular endothelium,
and brain) can contribute to this synthesis [150]. Primary bile acids are conjugated to glycine or taurine
and are secreted into the bile, then, via bile, into the duodenum. Hepatic primary bile acids emulsify
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fats and activate lipases. The microbiome of the gut (mostly in the large bowels) dehydroxylate and
deconjugate bile acids. Thus, primary bile acids are modified to produce secondary bile acids, including
lithocholic acid (LCA), deoxycholic acid (DCA), and ursodeoxycholic acid (UDCA) [151]. There are
16 bile acids in early life, while in adulthood there are 20 different bile acids in humans [124,152,153].
The majority of bile acids undergo reuptake via the portal circulation and are then transported to the
liver, where secondary bile acids are re-hydroxylated and re-conjugated for reuse. This cycle is called
the enterohepatic circulation of bile acids. A small fraction of the reabsorbed bile acids can enter the
systemic circulation [154] and systemic bile acids exert hormone-like, systemic effects [23,30,155–157].
The primary-to-secondary bile acid conversion is linked to the gut microbiome. Primarily,
colonic bacteria are responsible for bile acid conversion; nevertheless, upper segments of the
gastrointestinal tract may also play a role in bile acid transformation. Deconjugation takes place first,
followed by oxidation, dehydroxylation, and epimerization. Deconjugation is catalyzed by bile salt
hydrolases. Bacteroides fragilis, Bacteroides vulgatus, Listeria monocytogenes, Clostridium, Lactobacillus,
and Bifidobacterium possess bile salt hydrolases [124–129]. Oxidation and epimerization activities are
linked to intestinal Firmicutes (Clostridium, Eubacterium, and Ruminococcus), Bacteroides, and Escherichia,
while dehydroxylation is linked to Clostridia and Eubacteria [124–126,128]. The enzymes involved in
secondary bile acid production are assembled in the bile acid inducible (bai) operon in bacteria [151].
Bile acids have multiple receptors, including farnesoid-X-receptor (FXR), liver-X receptor (LXR),
Takeda G Protein-Coupled Receptor 5/G-protein-coupled bile acid receptor (TGR5), constitutive
androstane receptor (CAR), vitamin D receptor (VDR), and pregnane X receptor (PXR). These receptors
are nuclear receptors, except for TGR5. Through these receptors, bile acids impact on immune responses,
gastrointestinal mucosal barrier function, gestation [158], carcinogenesis [23,34], and metabolic
diseases [155,159].
Bile acid homeostasis is largely hampered in cancer and metabolic diseases [160]. Originally, bile
acids were regarded as procarcinogens [161]. However, recent advances suggest that some secondary
bile acids can behave as both pro- and anti-carcinogens, depending on the cancer in question and the
concentration of the bile acid present [23,34,105,107,162–169]. Bile acids also modulate the composition
of the microbiome [160,170–176] and facilitate bacterial translocation into tissues [177], a key step in
the carcinogenesis of pancreatic adenocarcinoma. Bacteria have different sensitivity for bile acids.
Enterococci are considered bile acid resistant bacteria, which may explain the reports showing increased
abundance of this bacteria in pancreatic adenocarcinoma [65,90,93].
Bile acid levels were reported to increase in pancreatic adenocarcinoma. A study comprised of
15 patients with pancreatic cancer and 15 patients with benign disease showed increasing trends in all
bile acid species detected in pancreatic cancer patients. Increases in unconjugated bile acid levels in
pancreatic adenocarcinoma patients were significant and surprisingly large (26 fold) [178].
Most bile acids have a carcinogenic role in pancreatic adenocarcinoma. Bile acids modulate risk
factors for pancreatic adenocarcinoma; bile acids impact pancreatitis and bile acid efflux disorders,
type II diabetes, obesity, and hyperlipidemia. Furthermore, bile acids reduce susceptibility to
apoptosis, induce inflammatory mediators, and may perturb membranes and cellular movement
(reviewed in [179]). Gallstones can obstruct the outflow of bile and, hence, can induce and sustain
pancreatitis [180], a risk factor for pancreatic adenocarcinoma [179,181,182]. Exposure of pre-malignant
pancreas ductal cells to bile may lead to carcinogenic transformation through inflammatory signaling,
as demonstrated in rodent and human data [183–186]. DCA, through binding to TGR5, can activate
EGFR, mitogen-activated protein kinase, and STAT3 signaling in pancreatic adenocarcinoma cells,
inducing cell cycle progression [187]. Interestingly, there seems to be a selectivity among bile acids,
as UDCA inhibits the epithelial-to-mesenchymal transition in pancreatic adenocarcinoma cell lines,
and in that regard, acts as an anti-carcinogenic factor [188].
Expression levels for VDR [189], FXR [190], and PXR [191] are higher in tumor tissue than in the
normal tissue of the pancreas. LXRβ, but not LXRα, is abundantly expressed in human pancreatic
adenocarcinoma cases [192]. In the serum of PDAC patients, components of the LXR/RXR system
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are enriched [193]. Furthermore, higher FXR expression correlates with higher TNM stage, shorter
survival, and poorer prognosis [190]. Higher PXR expression correlated with higher histological
grade of pancreatic adenocarcinoma [191]. Nevertheless, unexpectedly, enhanced PXR/RXRβ
expression correlated with smaller tumor size and the absence of lymph node metastases and longer
survival [191]. Additionally, LXR agonist treatments disrupted proliferation, cell-cycle progression,
and colony-formation in PDAC cells [194].
4.3. Polyamines
Polyamine metabolism is dysregulated in pancreatic adenocarcinoma [195]. The functional role of
polyamine biosynthesis in (human) pancreatic adenocarcinoma is highlighted by the fact that the effects
of the standard cytostatic therapies can be accentuated or ameliorated by modulation of the polyamine
cycle [196–200]. Cadaverine, putrescine, spermine, and spermidine are classified as polyamines, but
bacteria can produce other polyamines also [131,201].
Enzymes of the polyamine pathway had been identified in numerous species. However, the
functional characterization of polyamine biosynthesis is limited to a few species [131]. E. coli,
Enterococcus faecalis, Staphylococcus aureus, Haemophilus influenzae, Neisseria flava, Pseudomonas aeruginosa,
Campylobacter jejuni, Yersinia pestis, Vibrio cholerae, Bacteroides dorei, Bacteroides thetaiotaomicron, Bacteroides
fragilis, Bacillus subtilis, and Proteus mirabilis were shown to produce, accumulate, or need/use
polyamines [108,130,131].
Cadaverine is a decarboxylation product of lysine and the bacterial enzymes LdcC and CadA
are responsible for cadaverine biosynthesis [202,203]. Both the human body and bacteria can produce
cadaverine. Shigella flexneri, Shigella sonnei, Escherichia coli, and Streptococcus possess enzymes for
cadaverine biosynthesis [132]. Putrescine can be derived from arginine through decarboxylation, as is
the case in E. coli [108]. Polyamines support bacterial growth and biofilm formation and in many
pathogenic species are considered virulence factors [131].
A metabolomic and metatranscriptomic study of the fecal microbiome from a murine pancreatic
adenocarcinoma model [67] showed that bacterial polyamine biosynthetic capacity was upregulated
and aggravated by tumor progression. The main polyamines synthesized were putrescine, spermine,
and spermidine. In accordance with these results, serum polyamine levels were also higher in pancreatic
adenocarcinoma-bearing mice and patients. In contrast, Ren and co-workers [43] found that polyamine
biosynthesis and transport pathways were downregulated in samples from pancreatic adenocarcinoma
patients. Nevertheless, the lysine and putrescine transport systems were upregulated.
4.4. Bacterial Lipopolysaccharide (LPS)
Lipopolysaccharides, lypoglycans, or endotoxins are components of the bacterial outer membrane
in Gram-negative bacteria [204,205]. Although LPS is not a classical bacterial metabolite in the
strict sense, LPS seems to play a crucial role in the pathogenesis of pancreatic adenocarcinoma.
Lipopolysaccharides are built upon a lipid anchor to which a polysaccharide chain is attached.
The inherent role of LPS is to protect bacteria against toxins, antibiotics, or bile acids. However, LPS has
high immunogenic potential and is considered a member of the pathogen associated molecular patterns
(PAMPs). LPS elicits its effects through TLR4 and TLR2 receptors to induce innate immunity [204,205].
In pancreatic adenocarcinoma-associated oncobiosis, the proportion of LPS producing bacteria
(Prevotella, Hallella, and Enterobacter) increases [43]. In addition, TLR2, TLR4, and TLR9 [104] and the
downstream target of TLR4, MyD88 [40], are associated with pancreatic adenocarcinoma development.
Taken together, LPS-induced TLR signaling likely plays a key role in maintaining inflammation in
pancreatic adenocarcinoma.
4.5. Tryptophan Metabolites
Tryptophan is an amino acid with a very complex and intricate metabolism, in which bacterial
metabolism plays a major role. A considerable portion of tryptophan, 4–6%, is metabolized by bacteria
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to yield indol derivatives [206]. In germ-free mice, serum tryptophan levels increase, emphasizing the
volume of bacterial tryptophan degradation [133,207–210]. The bacterial metabolism of tryptophan
has multiple branches [133,206], described as follows:
(1) The decarboxylation of tryptophan yields tryptamine. Clostridium sporogenes and Ruminococcus
gnavus possess enzymes for tryptophan decarboxylation [133].
(2) Tryptophanase deaminates tryptophan to indole pyruvic acid, which is then metabolized to
indole. Indole can be further oxidized and the subsequent conjugation of sulphate yields indican.
Tryptophanase, denoted as TnaA, can be found in the tryptophanase operon [211]. Tryptophanase
expression is widespread among bacteria [212,213].
(3) Indole pyruvic acid can be decarboxylated to indole acetaldehyde. Indole acetaldehyde can be
converted to tryptophol or indole acetic acid. Indole acetic acid can be decarboxylated to yield
skatole or conjugated with glutamine to yield indole acetic acid-glutamine. The main genera for
this pathway are Lactobacillus, Clostridium, and Bacteroides [133].
(4) The reduction of indole pyruvic acid yields indole lactate, the dehydration of which yields indole
acrylic acid. This compound can be reduced to indole propionic acid. Indole propionic acid can
be further converted by human enzymes.
Tryptophan-derivatives (indoles) are ligands for the aryl hydrocarbon receptor (AHR) and can also
bind to the PXR receptor [214–216]. AHR activation is a key element in the regulation of the immune
system [133,217]. A tryptophan-poor diet has immunosuppressive effects in an AHR-dependent
fashion [218]. By modulating mucosal immunity through AHR, indole derivatives influence the
composition of the gut microbiome. For example, indole-derivatives can facilitate the expansion
of Lactobacillus reuteri and inhibit the growth of pathogenic bacteria [214,219–221]. Furthermore,
Lactobacillus utilizes tryptophan as an energy source [214].
Although direct data are missing for the effects of indole-derivatives in pancreatic adenocarcinoma,
the invasive behavior of pancreatic adenocarcinoma cells can be modulated through the selective
AHR modulators, Omeprazole and Tranilast [222]. Furthermore, as we noted above, a higher PXR
expression correlates with a higher histological grade of pancreatic adenocarcinoma, while enhanced
PXR/RXRβ expression correlates with a smaller tumor size, the absence of lymph node metastases, and
longer survival [191].
4.6. Other Metabolites
To date, two studies reported in silico reconstruction of metabolic pathways of the microbiome
in pancreatic adenocarcinoma. These data identify bacterial metabolites that potentially influence
pancreatic adenocarcinoma cells or carcinogenesis itself, thus, we review these data and provide a list
in Table 3.
Mendez and colleagues [67] reported a time course experiment using a murine model of
pancreatic adenocarcinoma. The results of this experiment revealed that the microbiome in pancreatic
adenocarcinoma shifted towards nucleotide, lipid, and polyamine biosynthesis that was accentuated
during the progression of the disease. Increased polyamine biosynthesis was confirmed by direct
measurement of polyamines in the serum of tumor-bearing mice and healthy controls and pancreatic
adenocarcinoma patients. In addition, hexitol fermentation, carbohydrate metabolism, and vitamin
biosynthesis and metabolism were upregulated.
The second study was a prospective study of 85 pancreatic adenocarcinoma patients and 57
matched healthy controls in which the fecal microbiome was assessed [43]. A decrease was observed
in various transport systems, amino acid metabolism, and core metabolic pathways in pancreatic
adenocarcinoma patients. Among the upregulated pathways were genes for amino acid metabolism,
carbohydrate metabolism, transport systems, and metabolic pathways.
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Table 3. Bacterial metabolic pathways dysregulated in pancreatic adenocarcinoma.
Study Direction of Regulationin Patients Biological Process Biochemical Process
[67] upregulated
Nucleotide biosynthesis
Lipid biosynthesis
Polyamine biosynthesis
Hexitol fermentation
Carbohydrate metabolism
Vitamin biosynthesis and metabolism
[43]
downregulated
transport systems
Phosphate transport system (M00222)
Cobalt transport system (M00245)
Mannopine transport system (M00301)
Glutamate transport system (M00233)
Trehalose-maltose transport system (M00204)
Spermidine-putrescine transport system (M00299)
amino acid metabolism
Histidine biosynthesis (M00026)
Glutamate transport system (M00233)
metabolic pathways
Complex I/NADH dehydrogenase (M00144)
Pentose phosphate pathway/non-oxidative phase (M00007)
V type ATPase (M00159)
Pyrimidine deoxyribonucleotide biosynthesis (M00053)
Pyruvate ferredoxin oxidoreductase (M00310)
upregulated
amino acid metabolism
Leucine biosynthesis (M00019)
Twin arginine translocation/Tat system (M00336)
Histidine degradation (M00045)
Methionine salvage pathway (M00034)
Lysine arginine ornithine transport system (M00225)
Dipeptide transport system (M00324)
Arginine transport system (M00229)
Histidine transport system (M00226)
carbohydrate
metabolism
Oligogalacturonide transport system (M00202)
Entner Doudoroff pathway (M00008)
transport systems
Putative spermidine putrescine transport system (M00193)
Microcin C transport system (M00349)
Putrescine transport system (M00300)
Sec secretion system (M00335)
Histidine transport system (M00226)
metabolic pathways
Pyridoxal biosynthesis (M00124), Citrate cycle (M00011)
Complex II/succinate dehydrogenase (M00150)
Glyoxylate cycle (M00012)
C5 isoprenoid biosynthesis/non-mevalonate pathway (M00096)
Ubiquinone biosynthesis (M00117)
Prokaryotic GABA biosynthesis (M00136)
Lipopolysaccharide biosynthesis (M00060)
Bacterial DNA polymerase III complex (M00260)
polyamine biosynthesis
and transport
Polyamine biosynthesis (M00133)
Spermidine putrescine transport system (M00299)
5. Supporting Clinical Decision Making, Diagnostic Applications
As we noted earlier, certain studies assessing the oncobiome in pancreatic adenocarcinoma
came to the conclusion that the composition of the oral [63,82,86,88,223], gut [43], pancreatic [102],
and fecal [100] microbiomes differ from the corresponding healthy microbiomes. Thus, the microbiomes
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can be used for diagnostic applications. Diagnostics can be useful for the assessment of the risk for
tumor development (i.e., tumor detection) [82], survival prediction [41,91], deducting etiology [100],
predicting mortality [89], and selecting between the forms of the disease (e.g., obstructive versus
non-obstructive forms [43]).
Most studies mentioned above had low patient numbers (tens of patients to a few hundred) and,
therefore, did not reach the level of statistical significance. When already existing shotgun sequencing
data of tumor DNA was assessed for the presence of bacterial DNA detected statistically [102], counts of
bacteria in tumors differed from the corresponding non-transformed tissues. Importantly, patterns were
identified that had suitable specificity and selectivity values for subsequent diagnostic applications.
Furthermore, these patterns were detectable in serum in the form of cell-free DNA, suggesting that
serum could be used for diagnostic applications [102]. In addition, oral swab or feces can be used as
easily accessible biomaterials for the detection of pancreatic adenocarcinoma [82,88,100].
As the detection of pancreatic adenocarcinoma is difficult at early (curable) stages, early detection
through detecting oncobiotic transformation has clear advantages for patients. The choice of antibiotics
used for premedication before surgical excision of pancreatic adenocarcinoma can also be based on the
composition of the pancreatic microbiome [92].
6. Future Directions
Oncobiosis in pancreatic adenocarcinoma is a complex process, involving multiple microbiome
compartments, including the oral, gastric, duodenal, ductal, pancreatic, and fecal compartments.
The bacterial colonization of the pancreas drives inflammation and probably facilitates the initiation
and progression of the disease to determine the aggressiveness of the disease. Furthermore, there
seems to be a large set of bacterial metabolites released into the circulation or tumor microenvironment
that has direct effects on the behavior of pancreatic adenocarcinoma cells (Figure 2).Cancers 2020, 12, x 16 of 27 
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Figure 2. Schematic representation of the role of oncobiosis in pancreatic adenocarcinoma.
Rows represent the spillover of the dysbiotic microbiome of the oral cavity, stomach, and bowels to the
pancreas and feces. Antineoplastic processes are shown in green and neoplastic processes are shown in
red. Abbreviations: UDCA—ursodeoxycholic acid, DCA—deoxycholic acid, LPS—lipopolysaccharide.
The involvement of bacterial metabolites is just coming of age in the microbiome field. In other
cancers, the involvement of the microbiome has gained ground quickly and holds promise for new
treatment modalities [224,225]. Studies on the in silico reconstruction of microbiome metabolism and
other circumstantial data suggest large changes to the bacterial metabolome, making it likely that such
metabolites will be identified and characterized in the future. It is important to note that in studies with
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bacterial metabolites, metabolites must be used in concentrations corresponding to serum or tissue
reference concentrations to avoid the non-physiological effects of supraphysiological concentrations.
Establishing the causative role of oncobiosis in pancreatic adenocarcinoma will facilitate the
assessment of how antibiotics, probiotics, or prebiotics may modulate the behavior of the disease in
analogy to other diseases and studies [59,60,226–228]. Dietary intervention or special diets can be
proposed to patients [229]. Thus, the study of the microbiome may change personalized medicine [100].
A better understanding of the oncobiome in pancreatic adenocarcinoma holds the promise of prolonging
survival in pancreatic adenocarcinoma.
Author Contributions: All authors contributed to data collection and the writing of the manuscript. All authors
have read and agreed to the published version of the manuscript.
Funding: Hungarian Scientific Research Fund: K123975; Hungarian Scientific Research Fund: PD124110;
Hungarian Scientific Research Fund: FK128387; Hungarian Scientific Research Fund: GINOP-2.3.2-15-2016-00006;
Hungarian Scientific Research Fund: EFOP-3.6.2-16-2017-0006; Hungarian Scientific Research Fund: K120669;
Magyar Tudományos Akadémia: Bolyai fellowship; Hungarian Scientific Research Fund: NKFIH-1150-6/2019;
Hungarian Scientific Research Fund: ÚNKP-19-4-DE-79.
Acknowledgments: Our work was supported by grants from the NKFIH (K123975, PD124110, FK128387,
GINOP-2.3.2-15-2016-00006, EFOP-3.6.2-16-2017-0006, K120669) and by the Faculty of Medicine at the University
of Debrecen. EM was supported by the Bolyai Fellowship from the Hungarian Academy of Sciences. The research
was financed by the Higher Education Institutional Excellence Program (NKFIH-1150-6/2019) of the Ministry of
Innovation and Technology in Hungary, within the framework of the Biotechnology thematic program of the
University of Debrecen. EM is supported by the ÚNKP-19-4-DE-79 New National Excellence Program of the
Ministry of Human Capacities.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Ducreux, M.; Cuhna, A.S.; Caramella, C.; Hollebecque, A.; Burtin, P.; Goere, D.; Seufferlein, T.;
Haustermans, K.; Van Laethem, J.L.; Conroy, T.; et al. Cancer of the pancreas: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015, 26, 56–68. [CrossRef]
2. Rawla, P.; Sunkara, T.; Gaduputi, V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk
Factors. World J. Oncol. 2019, 10, 10–27. [CrossRef]
3. Pei, X.; Song, F.; Wang, Z. Emerging incidence trends and application of curative treatments of pancreatic
cancer in the USA. Medicine 2019, 98, e17175. [CrossRef]
4. Rahib, L.; Smith, B.D.; Aizenberg, R.; Rosenzweig, A.B.; Fleshman, J.M.; Matrisian, L.M. Projecting cancer
incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United
States. Cancer Res. 2014, 74, 2913–2921. [CrossRef]
5. Chun, Y.S.; Pawlik, T.M.; Vauthey, J.N. 8th Edition of the AJCC Cancer Staging Manual: Pancreas and
Hepatobiliary Cancers. Ann. Surg. Oncol. 2018, 25, 845–847. [CrossRef] [PubMed]
6. Lowery, M.A.; Kelsen, D.P.; Capanu, M.; Smith, S.C.; Lee, J.W.; Stadler, Z.K.; Moore, M.J.; Kindler, H.L.;
Golan, T.; Segal, A.; et al. Phase II trial of veliparib in patients with previously treated BRCA-mutated
pancreas ductal adenocarcinoma. Eur. J. Cancer 2018, 89, 19–26. [CrossRef] [PubMed]
7. Silvestris, N.; Longo, V.; Cellini, F.; Reni, M.; Bittoni, A.; Cataldo, I.; Partelli, S.; Falconi, M.; Scarpa, A.;
Brunetti, O.; et al. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Crit. Rev.
Oncol. Hematol. 2016, 98, 309–324. [CrossRef] [PubMed]
8. Yeo, T.P. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin. Oncol.
2015, 42, 8–18. [CrossRef] [PubMed]
9. Waddell, N.; Pajic, M.; Patch, A.M.; Chang, D.K.; Kassahn, K.S.; Bailey, P.; Johns, A.L.; Miller, D.; Nones, K.;
Quek, K.; et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015, 518,
495–501. [CrossRef] [PubMed]
10. Hashimoto, D.; Arima, K.; Yokoyama, N.; Chikamoto, A.; Taki, K.; Inoue, R.; Kaida, T.; Higashi, T.; Nitta, H.;
Ohmuraya, M.; et al. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma. Pancreas
2016, 45, 1111–1114. [CrossRef]
11. Schwabe, R.F.; Jobin, C. The microbiome and cancer. Nat. Rev. Cancer 2013, 13, 800–812. [CrossRef] [PubMed]
Cancers 2020, 12, 1068 17 of 27
12. Flores, R.; Shi, J.; Fuhrman, B.; Xu, X.; Veenstra, T.D.; Gail, M.H.; Gajer, P.; Ravel, J.; Goedert, J.J. Fecal
microbial determinants of fecal and systemic estrogens and estrogen metabolites: A cross-sectional study.
J. Transl. Med. 2012, 10, 253. [CrossRef] [PubMed]
13. Goedert, J.J.; Jones, G.; Hua, X.; Xu, X.; Yu, G.; Flores, R.; Falk, R.T.; Gail, M.H.; Shi, J.; Ravel, J.; et al.
Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women:
A population-based case-control pilot study. J. Natl. Cancer Inst. 2015, 107, 147. [CrossRef] [PubMed]
14. Robinson, K.M.; Crabtree, J.; Mattick, J.S.; Anderson, K.E.; Dunning Hotopp, J.C. Distinguishing potential
bacteria-tumor associations from contamination in a secondary data analysis of public cancer genome
sequence data. Microbiome 2017. [CrossRef] [PubMed]
15. Chen, J.; Pitmon, E.; Wang, K. Microbiome, inflammation and colorectal cancer. Semin. Immunol. 2017, 32,
43–53. [CrossRef] [PubMed]
16. Picardo, S.L.; Coburn, B.; Hansen, A.R. The microbiome and cancer for clinicians. Crit. Rev. Oncol. Hematol.
2019, 141, 1–12. [CrossRef]
17. Saus, E.; Iraola-Guzman, S.; Willis, J.R.; Brunet-Vega, A.; Gabaldon, T. Microbiome and colorectal cancer:
Roles in carcinogenesis and clinical potential. Mol. Asp. Med. 2019. [CrossRef]
18. De Martel, C.; Ferlay, J.; Franceschi, S.; Vignat, J.; Bray, F.; Forman, D.; Plummer, M. Global burden of cancers
attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol. 2012, 13, 607–615. [CrossRef]
19. Miko, E.; Vida, A.; Bai, P. Translational aspects of the microbiome-to be exploited. Cell Biol. Toxicol. 2016, 32,
153–156. [CrossRef]
20. Hall, A.; Versalovic, J. Microbial Metabolism in the Mammalian Gut: Molecular Mechanisms and Clinical
Implications. J. Pediatr. Gastroenterol. Nutr. 2018, 66, S72–S79. [CrossRef]
21. Zitvogel, L.; Ayyoub, M.; Routy, B.; Kroemer, G. Microbiome and Anticancer Immunosurveillance. Cell 2016,
165, 276–287. [CrossRef] [PubMed]
22. Kovács, T.; Mikó, E.; Vida, A.; Sebo˝, É.; Toth, J.; Csonka, T.; Boratkó, A.; Ujlaki, G.; Lente, G.; Kovács, P.; et al.
Cadaverine, a metabolite of the microbiome, reduces breast cancer aggressiveness through trace amino acid
receptors. Sci. Rep. 2019, 9, 1300. [CrossRef] [PubMed]
23. Miko, E.; Vida, A.; Kovacs, T.; Ujlaki, G.; Trencsenyi, G.; Marton, J.; Sari, Z.; Kovacs, P.; Boratko, A.; Hujber, Z.;
et al. Lithocholic acid, a bacterial metabolite reduces breast cancer cell proliferation and aggressiveness.
Biochim. Biophys. Acta 2018, 1859, 958–974. [CrossRef] [PubMed]
24. Buchta Rosean, C.; Bostic, R.R.; Ferey, J.C.M.; Feng, T.Y.; Azar, F.N.; Tung, K.S.; Dozmorov, M.G.; Smirnova, E.;
Bos, P.D.; Rutkowski, M.R. Preexisting Commensal Dysbiosis Is a Host-Intrinsic Regulator of Tissue
Inflammation and Tumor Cell Dissemination in Hormone Receptor-Positive Breast Cancer. Cancer Res. 2019,
79, 3662–3675. [CrossRef]
25. Ingman, W.V. The Gut Microbiome: A New Player in Breast Cancer Metastasis. Cancer Res. 2019, 79,
3539–3541. [CrossRef]
26. Viaud, S.; Daillere, R.; Boneca, I.G.; Lepage, P.; Pittet, M.J.; Ghiringhelli, F.; Trinchieri, G.; Goldszmid, R.;
Zitvogel, L. Harnessing the intestinal microbiome for optimal therapeutic immunomodulation. Cancer Res.
2014, 74, 4217–4221. [CrossRef]
27. Routy, B.; Le Chatelier, E.; Derosa, L.; Duong, C.P.M.; Alou, M.T.; Daillere, R.; Fluckiger, A.; Messaoudene, M.;
Rauber, C.; Roberti, M.P.; et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against
epithelial tumors. Science 2018, 359, 91–97. [CrossRef]
28. Elkrief, A.; Derosa, L.; Kroemer, G.; Zitvogel, L.; Routy, B. The negative impact of antibiotics on outcomes in
cancer patients treated with immunotherapy: A new independent prognostic factor? Ann. Oncol. 2019, 30,
1572–1579. [CrossRef]
29. Kovacs, T.; Miko, E.; Ujlaki, G.; Sari, Z.; Bai, P. The Microbiome as a Component of the Tumor
Microenvironment. Adv. Exp. Med. Biol. 2020, 1225, 137–153.
30. Miko, E.; Kovacs, T.; Sebo, E.; Toth, J.; Csonka, T.; Ujlaki, G.; Sipos, A.; Szabo, J.; Mehes, G.; Bai, P.
Microbiome-Microbial Metabolome-Cancer Cell Interactions in Breast Cancer-Familiar, but Unexplored.
Cells 2019, 8, 293. [CrossRef]
31. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef]
[PubMed]
32. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70. [CrossRef]
Cancers 2020, 12, 1068 18 of 27
33. Zitvogel, L.; Daillere, R.; Roberti, M.P.; Routy, B.; Kroemer, G. Anticancer effects of the microbiome and its
products. Nat. Rev. Microbiol. 2017, 15, 465–478. [CrossRef] [PubMed]
34. Kovács, P.; Csonka, T.; Kovács, T.; Sári, Z.; Ujlaki, G.; Sipos, A.; Karányi, Z.; Szeo˝cs, D.; Hegedu˝s, C.;
Uray, K.; et al. Lithocholic acid, a metabolite of the microbiome, increases oxidative stress in breast cancer.
Cancers 2019, 11, 1255. [CrossRef] [PubMed]
35. Vergara, D.; Simeone, P.; Damato, M.; Maffia, M.; Lanuti, P.; Trerotola, M. The Cancer Microbiota: EMT and
Inflammation as Shared Molecular Mechanisms Associated with Plasticity and Progression. J. Oncol. 2019.
[CrossRef] [PubMed]
36. Lau, A.; Villeneuve, N.F.; Sun, Z.; Wong, P.K.; Zhang, D.D. Dual roles of Nrf2 in cancer. Pharmacol. Res. 2008,
58, 262–270. [CrossRef] [PubMed]
37. Jezierska-Drutel, A.; Rosenzweig, S.A.; Neumann, C.A. Role of oxidative stress and the microenvironment in
breast cancer development and progression. Adv. Cancer Res. 2013, 119, 107–125.
38. Smolková, K.; Mikó, E.; Kovács, T.; Leguina-Ruzzi, A.; Sipos, A.; Bai, P. NRF2 in regulating cancer metabolism.
Antioxid. Redox Signal. 2020. [CrossRef]
39. Pagliari, D.; Saviano, A.; Newton, E.E.; Serricchio, M.L.; Dal Lago, A.A.; Gasbarrini, A.; Cianci, R.
Gut Microbiota-Immune System Crosstalk and Pancreatic Disorders. Mediators Inflamm. 2018, 2018,
7946431. [CrossRef]
40. Ochi, A.; Nguyen, A.H.; Bedrosian, A.S.; Mushlin, H.M.; Zarbakhsh, S.; Barilla, R.; Zambirinis, C.P.;
Fallon, N.C.; Rehman, A.; Pylayeva-Gupta, Y.; et al. MyD88 inhibition amplifies dendritic cell capacity to
promote pancreatic carcinogenesis via Th2 cells. J. Exp. Med. 2012, 209, 1671–1687. [CrossRef]
41. Pushalkar, S.; Hundeyin, M.; Daley, D.; Zambirinis, C.P.; Kurz, E.; Mishra, A.; Mohan, N.; Aykut, B.; Usyk, M.;
Torres, L.E.; et al. The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and
Adaptive Immune Suppression. Cancer Discov. 2018, 8, 403–416. [CrossRef] [PubMed]
42. Sethi, V.; Kurtom, S.; Tarique, M.; Lavania, S.; Malchiodi, Z.; Hellmund, L.; Zhang, L.; Sharma, U.; Giri, B.;
Garg, B.; et al. Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response.
Gastroenterology 2018, 155, 33–37. [CrossRef] [PubMed]
43. Ren, Z.; Jiang, J.; Xie, H.; Li, A.; Lu, H.; Xu, S.; Zhou, L.; Zhang, H.; Cui, G.; Chen, X.; et al. Gut microbial profile
analysis by MiSeq sequencing of pancreatic carcinoma patients in China. Oncotarget 2017, 8, 95176–95191.
[CrossRef] [PubMed]
44. Gopalakrishnan, V.; Spencer, C.N.; Nezi, L.; Reuben, A.; Andrews, M.C.; Karpinets, T.V.; Prieto, P.A.;
Vicente, D.; Hoffman, K.; Wei, S.C.; et al. Gut microbiome modulates response to anti-PD-1 immunotherapy
in melanoma patients. Science 2018, 359, 97–103. [CrossRef] [PubMed]
45. Buchta Rosean, C.; Feng, T.Y.; Azar, F.N.; Rutkowski, M.R. Impact of the microbiome on cancer progression
and response to anti-cancer therapies. Adv. Cancer Res. 2019, 143, 255–294. [CrossRef] [PubMed]
46. Valastyan, S.; Weinberg, R.A. Tumor metastasis: Molecular insights and evolving paradigms. Cell 2011, 147,
275–292. [CrossRef] [PubMed]
47. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119,
1420–1428. [CrossRef]
48. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.;
Shipitsin, M.; et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell
2008, 133, 704–715. [CrossRef]
49. Biedermann, L.; Zeitz, J.; Mwinyi, J.; Sutter-Minder, E.; Rehman, A.; Ott, S.J.; Steurer-Stey, C.; Frei, A.; Frei, P.;
Scharl, M.; et al. Smoking cessation induces profound changes in the composition of the intestinal microbiota
in humans. PLoS ONE 2013, 8, e59260. [CrossRef]
50. Schulz, M.D.; Atay, C.; Heringer, J.; Romrig, F.K.; Schwitalla, S.; Aydin, B.; Ziegler, P.K.; Varga, J.; Reindl, W.;
Pommerenke, C.; et al. High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently
of obesity. Nature 2014, 514, 508–512. [CrossRef]
51. Zarrinpar, A.; Chaix, A.; Panda, S. Daily Eating Patterns and Their Impact on Health and Disease.
Trends Endocrinol. Metab. 2016, 27, 69–83. [CrossRef] [PubMed]
52. Zarrinpar, A.; Chaix, A.; Yooseph, S.; Panda, S. Diet and feeding pattern affect the diurnal dynamics of the
gut microbiome. Cell Metab. 2014, 20, 1006–1017. [CrossRef]
53. Paschos, G.K.; FitzGerald, G.A. Circadian Clocks and Metabolism: Implications for Microbiome and Aging.
Trends Genet. 2017, 33, 760–769. [CrossRef] [PubMed]
Cancers 2020, 12, 1068 19 of 27
54. Zhang, H.; Cherian, R.; Jin, K. Systemic milieu and age-related deterioration. Geroscience 2019, 41, 275–284.
[CrossRef] [PubMed]
55. Saffrey, M.J. Aging of the mammalian gastrointestinal tract: A complex organ system. Age 2014, 36, 9603.
[CrossRef]
56. Singh, H.; Torralba, M.G.; Moncera, K.J.; DiLello, L.; Petrini, J.; Nelson, K.E.; Pieper, R. Gastro-intestinal and
oral microbiome signatures associated with healthy aging. Geroscience 2019. [CrossRef]
57. Devaraj, S.; Hemarajata, P.; Versalovic, J. The human gut microbiome and body metabolism: Implications for
obesity and diabetes. Clin. Chem. 2013, 59, 617–628. [CrossRef]
58. Ticinesi, A.; Lauretani, F.; Tana, C.; Nouvenne, A.; Ridolo, E.; Meschi, T. Exercise and immune system as
modulators of intestinal microbiome: Implications for the gut-muscle axis hypothesis. Exerc. Immunol. Rev.
2019, 25, 84–95.
59. Friedman, G.D.; Oestreicher, N.; Chan, J.; Quesenberry, C.P., Jr.; Udaltsova, N.; Habel, L.A. Antibiotics and
risk of breast cancer: Up to 9 years of follow-up of 2.1 million women. Cancer Epidemiol. Biomark. Prev. 2006,
15, 2102–2106. [CrossRef]
60. Mendoza, L. Potential effect of probiotics in the treatment of breast cancer. Oncol. Rev. 2019, 13, 422.
[CrossRef]
61. Ranjbar, S.; Seyednejad, S.A.; Azimi, H.; Rezaeizadeh, H.; Rahimi, R. Emerging Roles of Probiotics in
Prevention and Treatment of Breast Cancer: A Comprehensive Review of Their Therapeutic Potential.
Nutr. Cancer 2019, 71, 1–12. [CrossRef]
62. Lindkvist, B.; Johansen, D.; Borgstrom, A.; Manjer, J. A prospective study of Helicobacter pylori in relation to
the risk for pancreatic cancer. BMC Cancer 2008. [CrossRef] [PubMed]
63. Farrell, J.J.; Zhang, L.; Zhou, H.; Chia, D.; Elashoff, D.; Akin, D.; Paster, B.J.; Joshipura, K.; Wong, D.T.
Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 2012,
61, 582–588. [CrossRef] [PubMed]
64. Mei, Q.X.; Huang, C.L.; Luo, S.Z.; Zhang, X.M.; Zeng, Y.; Lu, Y.Y. Characterization of the duodenal bacterial
microbiota in patients with pancreatic head cancer vs. healthy controls. Pancreatology 2018, 18, 438–445.
[CrossRef] [PubMed]
65. Thomas, R.M.; Gharaibeh, R.Z.; Gauthier, J.; Beveridge, M.; Pope, J.L.; Guijarro, M.V.; Yu, Q.; He, Z.;
Ohland, C.; Newsome, R.; et al. Intestinal microbiota enhances pancreatic carcinogenesis in preclinical
models. Carcinogenesis 2018, 39, 1068–1078. [CrossRef]
66. Archibugi, L.; Signoretti, M.; Capurso, G. The Microbiome and Pancreatic Cancer: An Evidence-based
Association? J. Clin. Gastroenterol. 2018, 52, S82–S85. [CrossRef]
67. Mendez, R.; Kesh, K.; Arora, N.; Di Martino, L.; McAllister, F.; Merchant, N.; Banerjee, S.; Banerjee, S.
Microbial dysbiosis and polyamine metabolism as predictive markers for early detection of pancreatic cancer.
Carcinogenesis 2019, 1. [CrossRef]
68. Aykut, B.; Pushalkar, S.; Chen, R.; Li, Q.; Abengozar, R.; Kim, J.I.; Shadaloey, S.A.; Wu, D.; Preiss, P.; Verma, N.;
et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature 2019, 574,
264–267. [CrossRef]
69. Frulloni, L.; Lunardi, C.; Simone, R.; Dolcino, M.; Scattolini, C.; Falconi, M.; Benini, L.; Vantini, I.; Corrocher, R.;
Puccetti, A. Identification of a novel antibody associated with autoimmune pancreatitis. N. Engl. J. Med.
2009, 361, 2135–2142. [CrossRef]
70. Risch, H.A.; Lu, L.; Kidd, M.S.; Wang, J.; Zhang, W.; Ni, Q.; Gao, Y.T.; Yu, H. Helicobacter pylori seropositivities
and risk of pancreatic carcinoma. Cancer Epidemiol. Biomark. Prev. 2014, 23, 172–178. [CrossRef]
71. Wang, Y.; Zhang, F.C.; Wang, Y.J. Helicobacter pylori and pancreatic cancer risk: A meta- analysis based on
2049 cases and 2861 controls. Asian Pac. J. Cancer Prev. 2014, 15, 4449–4454. [CrossRef] [PubMed]
72. Rabelo-Goncalves, E.M.; Roesler, B.M.; Zeitune, J.M. Extragastric manifestations of Helicobacter pylori
infection: Possible role of bacterium in liver and pancreas diseases. World J. Hepatol. 2015, 7, 2968–2979.
[CrossRef] [PubMed]
73. Chen, X.Z.; Wang, R.; Chen, H.N.; Hu, J.K. Cytotoxin-Associated Gene A-Negative Strains of Helicobacter
pylori as a Potential Risk Factor of Pancreatic Cancer: A Meta-Analysis Based on Nested Case-Control
Studies. Pancreas 2015, 44, 1340–1344. [CrossRef] [PubMed]
74. Maisonneuve, P.; Lowenfels, A.B. Risk factors for pancreatic cancer: A summary review of meta-analytical
studies. Int. J. Epidemiol. 2015, 44, 186–198. [CrossRef] [PubMed]
Cancers 2020, 12, 1068 20 of 27
75. Ertz-Archambault, N.; Keim, P.; Von Hoff, D. Microbiome and pancreatic cancer: A comprehensive topic
review of literature. World J. Gastroenterol. 2017, 23, 1899–1908. [CrossRef] [PubMed]
76. Tenti, P.; Aguzzi, A.; Riva, C.; Usellini, L.; Zappatore, R.; Bara, J.; Samloff, I.M.; Solcia, E. Ovarian mucinous
tumors frequently express markers of gastric, intestinal, and pancreatobiliary epithelial cells. Cancer 1992, 69,
2131–2142. [CrossRef]
77. Ogrendik, M. Periodontal Pathogens in the Etiology of Pancreatic Cancer. Gastrointest. Tumors. 2017, 3,
125–127. [CrossRef]
78. Wei, M.Y.; Shi, S.; Liang, C.; Meng, Q.C.; Hua, J.; Zhang, Y.Y.; Liu, J.; Zhang, B.; Xu, J.; Yu, X.J. The microbiota
and microbiome in pancreatic cancer: More influential than expected. Mol. Cancer 2019, 18, 97. [CrossRef]
79. Zambirinis, C.P.; Pushalkar, S.; Saxena, D.; Miller, G. Pancreatic cancer, inflammation, and microbiome.
Cancer J. 2014, 20, 195–202. [CrossRef]
80. Mima, K.; Nakagawa, S.; Sawayama, H.; Ishimoto, T.; Imai, K.; Iwatsuki, M.; Hashimoto, D.; Baba, Y.;
Yamashita, Y.I.; Yoshida, N.; et al. The microbiome and hepatobiliary-pancreatic cancers. Cancer Lett. 2017,
402, 9–15. [CrossRef]
81. Hujoel, P.P.; Drangsholt, M.; Spiekerman, C.; Weiss, N.S. An exploration of the periodontitis-cancer association.
Ann. Epidemiol. 2003, 13, 312–316. [CrossRef]
82. Michaud, D.S.; Izard, J.; Wilhelm-Benartzi, C.S.; You, D.H.; Grote, V.A.; Tjonneland, A.; Dahm, C.C.;
Overvad, K.; Jenab, M.; Fedirko, V.; et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a
large European prospective cohort study. Gut 2013, 62, 1764–1770. [CrossRef] [PubMed]
83. Torres, P.J.; Fletcher, E.M.; Gibbons, S.M.; Bouvet, M.; Doran, K.S.; Kelley, S.T. Characterization of the salivary
microbiome in patients with pancreatic cancer. PeerJ 2015, 3, e1373. [CrossRef]
84. Nieminen, M.T.; Listyarifah, D.; Hagstrom, J.; Haglund, C.; Grenier, D.; Nordstrom, D.; Uitto, V.J.;
Hernandez, M.; Yucel-Lindberg, T.; Tervahartiala, T.; et al. Treponema denticola chymotrypsin-like
proteinase may contribute to orodigestive carcinogenesis through immunomodulation. Br. J. Cancer 2018,
118, 428–434. [CrossRef] [PubMed]
85. Fan, X.; Alekseyenko, A.V.; Wu, J.; Peters, B.A.; Jacobs, E.J.; Gapstur, S.M.; Purdue, M.P.; Abnet, C.C.;
Stolzenberg-Solomon, R.; Miller, G.; et al. Human oral microbiome and prospective risk for pancreatic cancer:
A population-based nested case-control study. Gut 2018, 67, 120–127. [CrossRef] [PubMed]
86. Lu, H.; Ren, Z.; Li, A.; Li, J.; Xu, S.; Zhang, H.; Jiang, J.; Yang, J.; Luo, Q.; Zhou, K.; et al. Tongue coating
microbiome data distinguish patients with pancreatic head cancer from healthy controls. J. Oral Microbiol.
2019, 11, 1563409. [CrossRef]
87. Gaiser, R.A.; Halimi, A.; Alkharaan, H.; Lu, L.; Davanian, H.; Healy, K.; Hugerth, L.W.; Ateeb, Z.; Valente, R.;
Fernandez Moro, C.; et al. Enrichment of oral microbiota in early cystic precursors to invasive pancreatic
cancer. Gut 2019, 68, 2186–2194. [CrossRef]
88. Vogtmann, E.; Han, Y.; Caporaso, J.G.; Bokulich, N.; Mohamadkhani, A.; Moayyedkazemi, A.; Hua, X.;
Kamangar, F.; Wan, Y.; Suman, S.; et al. Oral microbial community composition is associated with pancreatic
cancer: A case-control study in Iran. Cancer Med. 2020, 9, 797–806. [CrossRef]
89. Mitsuhashi, K.; Nosho, K.; Sukawa, Y.; Matsunaga, Y.; Ito, M.; Kurihara, H.; Kanno, S.; Igarashi, H.; Naito, T.;
Adachi, Y.; et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features
and prognosis. Oncotarget 2015, 6, 7209–7220. [CrossRef]
90. Maekawa, T.; Fukaya, R.; Takamatsu, S.; Itoyama, S.; Fukuoka, T.; Yamada, M.; Hata, T.; Nagaoka, S.;
Kawamoto, K.; Eguchi, H.; et al. Possible involvement of Enterococcus infection in the pathogenesis of
chronic pancreatitis and cancer. Biochem. Biophys. Res. Commun. 2018, 506, 962–969. [CrossRef]
91. Riquelme, E.; Zhang, Y.; Zhang, L.; Montiel, M.; Zoltan, M.; Dong, W.; Quesada, P.; Sahin, I.; Chandra, V.;
San Lucas, A.; et al. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes.
Cell 2019, 178, 795–806. [CrossRef] [PubMed]
92. Swan, C.D.; Nahm, C.; Samra, J.S.; Mittal, A.; Figtree, M. Microbiology of pancreatoduodenectomy and
recommendations for antimicrobial prophylaxis. ANZ J. Surg. 2019, 19, 15560. [CrossRef] [PubMed]
93. Di Carlo, P.; Serra, N.; D’Arpa, F.; Agrusa, A.; Gulotta, G.; Fasciana, T.; Rodolico, V.; Giammanco, A.; Sergi, C.
The microbiota of the bilio-pancreatic system: A cohort, STROBE-compliant study. Infect. Drug Resist. 2019,
12, 1513–1527. [CrossRef] [PubMed]
Cancers 2020, 12, 1068 21 of 27
94. Del Castillo, E.; Meier, R.; Chung, M.; Koestler, D.C.; Chen, T.; Paster, B.J.; Charpentier, K.P.; Kelsey, K.T.;
Izard, J.; Michaud, D.S. The Microbiomes of Pancreatic and Duodenum Tissue Overlap and Are Highly
Subject Specific but Differ between Pancreatic Cancer and Noncancer Subjects. Cancer Epidemiol. Biomark. Prev.
2019, 28, 370–383. [CrossRef] [PubMed]
95. Boursi, B.; Mamtani, R.; Haynes, K.; Yang, Y.X. Recurrent antibiotic exposure may promote cancer
formation–Another step in understanding the role of the human microbiota? Eur. J. Cancer 2015, 51,
2655–2664. [CrossRef]
96. Tsuji, Y.; Watanabe, T.; Kudo, M.; Arai, H.; Strober, W.; Chiba, T. Sensing of commensal organisms by the
intracellular sensor NOD1 mediates experimental pancreatitis. Immunity 2012, 37, 326–338. [CrossRef]
[PubMed]
97. Leal-Lopes, C.; Velloso, F.J.; Campopiano, J.C.; Sogayar, M.C.; Correa, R.G. Roles of Commensal Microbiota
in Pancreas Homeostasis and Pancreatic Pathologies. J. Diabetes Res. 2015, 2015, 284680. [CrossRef]
98. Metagenomics. Alpha and Beta Diversity. Available online: http://www.metagenomics.wiki/pdf/definition/
alpha-beta-diversity (accessed on 20 April 2020).
99. Vida, A.; Bodrogi, B.L.; Balogh, B.; Bai, P. Taxamat: Automated biodiversity data management tool –
Implications for microbiome studies. Physiol. Int. 2020. [CrossRef]
100. Half, E.; Keren, N.; Reshef, L.; Dorfman, T.; Lachter, I.; Kluger, Y.; Reshef, N.; Knobler, H.; Maor, Y.; Stein, A.;
et al. Fecal microbiome signatures of pancreatic cancer patients. Sci. Rep. 2019, 9, 16801. [CrossRef]
101. Michaud, D.S. Role of bacterial infections in pancreatic cancer. Carcinogenesis 2013, 34, 2193–2197. [CrossRef]
102. Poore, G.D.; Kopylova, E.; Zhu, Q.; Carpenter, C.; Fraraccio, S.; Wandro, S.; Kosciolek, T.; Janssen, S.;
Metcalf, J.; Song, S.J.; et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach.
Nature 2020, 579, 567–574. [CrossRef] [PubMed]
103. Hujoel, P.P.; Drangsholt, M.; Spiekerman, C.; DeRouen, T.A. Periodontitis-systemic disease associations in
the presence of smoking–causal or coincidental? Periodontol 2002, 30, 51–60. [CrossRef] [PubMed]
104. Grimmig, T.; Moench, R.; Kreckel, J.; Haack, S.; Rueckert, F.; Rehder, R.; Tripathi, S.; Ribas, C.; Chandraker, A.;
Germer, C.T.; et al. Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and
VEGF/PDGF Expression in Human Pancreatic Cancer. Int. J. Mol. Sci. 2016, 17, 2060. [CrossRef] [PubMed]
105. Yoshimoto, S.; Loo, T.M.; Atarashi, K.; Kanda, H.; Sato, S.; Oyadomari, S.; Iwakura, Y.; Oshima, K.; Morita, H.;
Hattori, M.; et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence
secretome. Nature 2013, 499, 97–101. [CrossRef]
106. Ridlon, J.M.; Bajaj, J.S. The human gut sterolbiome: Bile acid-microbiome endocrine aspects and therapeutics.
Acta Pharm. Sin. B 2015, 5, 99–105. [CrossRef]
107. Zeng, H.; Umar, S.; Rust, B.; Lazarova, D.; Bordonaro, M. Secondary Bile Acids and Short Chain Fatty Acids
in the Colon: A Focus on Colonic Microbiome, Cell Proliferation, Inflammation, and Cancer. Int. J. Mol. Sci.
2019, 20, 1214. [CrossRef]
108. Sittipo, P.; Shim, J.W.; Lee, Y.K. Microbial Metabolites Determine Host Health and the Status of Some Diseases.
Int. J. Mol. Sci. 2019, 20, 5296. [CrossRef]
109. Tan, J.; McKenzie, C.; Potamitis, M.; Thorburn, A.N.; Mackay, C.R.; Macia, L. The role of short-chain Fatty
acids in health and disease. Adv. Immunol. 2014, 121, 91–119.
110. Morrison, D.J.; Preston, T. Formation of short chain fatty acids by the gut microbiota and their impact on
human metabolism. Gut Microbes. 2016, 7, 189–200. [CrossRef]
111. Den Besten, G.; van Eunen, K.; Groen, A.K.; Venema, K.; Reijngoud, D.J.; Bakker, B.M. The role of short-chain
fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid. Res. 2013, 54,
2325–2340. [CrossRef]
112. Lin, Y.H.; Chen, Y.; Smith, T.C., II; Karna, S.L.R.; Seshu, J. Short-Chain Fatty Acids Alter Metabolic and
Virulence Attributes of Borrelia burgdorferi. Infect. Immun. 2018, 86. [CrossRef] [PubMed]
113. Cherrington, C.A.; Hinton, M.; Pearson, G.R.; Chopra, I. Short-chain organic acids at ph 5.0 kill Escherichia
coli and Salmonella spp. without causing membrane perturbation. J. Appl. Bacteriol. 1991, 70, 161–165.
[CrossRef] [PubMed]
114. Duncan, S.H.; Louis, P.; Thomson, J.M.; Flint, H.J. The role of pH in determining the species composition of
the human colonic microbiota. Environ. Microbiol. 2009, 11, 2112–2122. [CrossRef] [PubMed]
115. Prohaszka, L.; Jayarao, B.M.; Fabian, A.; Kovacs, S. The role of intestinal volatile fatty acids in the Salmonella
shedding of pigs. Zentralbl. Veterinarmed. B 1990, 37, 570–574. [CrossRef] [PubMed]
Cancers 2020, 12, 1068 22 of 27
116. Fachi, J.L.; Secca, C.; Rodrigues, P.B.; Mato, F.C.P.; Di Luccia, B.; Felipe, J.S.; Pral, L.P.; Rungue, M.; Rocha, V.M.;
Sato, F.T.; et al. Acetate coordinates neutrophil and ILC3 responses against C. difficile through FFAR2. J. Exp.
Med. 2020, 217, 133544. [CrossRef]
117. Levy, M.; Thaiss, C.A.; Elinav, E. Metabolites: Messengers between the microbiota and the immune system.
Genes Dev. 2016, 30, 1589–1597. [CrossRef]
118. Derrien, M.; Vaughan, E.E.; Plugge, C.M.; de Vos, W.M. Akkermansia muciniphila gen. nov., sp. nov., a
human intestinal mucin-degrading bacterium. Int. J. Syst. Evol. Microbiol. 2004, 54, 1469–1476. [CrossRef]
119. Reichardt, N.; Duncan, S.H.; Young, P.; Belenguer, A.; McWilliam Leitch, C.; Scott, K.P.; Flint, H.J.; Louis, P.
Phylogenetic distribution of three pathways for propionate production within the human gut microbiota.
ISME J. 2014, 8, 1323–1335. [CrossRef]
120. Fernández, J.; Redondo-Blanco, S.; Gutiérrez-del-Río, I.; Miguélez, E.M.; Villar, C.J.; Lombó, F. Colon
microbiota fermentation of dietary prebiotics towards short-chain fatty acids and their roles as
anti-inflammatory and antitumour agents: A review. J. Funct. Foods 2016, 25, 511–522. [CrossRef]
121. Koh, A.; De Vadder, F.; Kovatcheva-Datchary, P.; Backhed, F. From Dietary Fiber to Host Physiology:
Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell 2016, 165, 1332–1345. [CrossRef]
122. Louis, P.; Young, P.; Holtrop, G.; Flint, H.J. Diversity of human colonic butyrate-producing bacteria revealed by
analysis of the butyryl-CoA:acetate CoA-transferase gene. Environ. Microbiol. 2010, 12, 304–314. [CrossRef]
[PubMed]
123. Kirkup, B.; McKee, A.; Makin, K.; Paveley, J.; Caim, S.; Alcon-Giner, C.; Leclaire, C.; Dalby, M.; Le Gall, G.;
Andrusaite, A.; et al. Perturbation of the gut microbiota by antibiotics results in accelerated breast tumour
growth and metabolic dysregulation. BioRxiv 2019. [CrossRef]
124. Gerard, P. Metabolism of cholesterol and bile acids by the gut microbiota. Pathogens 2013, 3, 14–24. [CrossRef]
[PubMed]
125. Ridlon, J.M.; Harris, S.C.; Bhowmik, S.; Kang, D.J.; Hylemon, P.B. Consequences of bile salt biotransformations
by intestinal bacteria. Gut Microbes. 2016, 7, 22–39. [CrossRef] [PubMed]
126. Long, S.L.; Gahan, C.G.M.; Joyce, S.A. Interactions between gut bacteria and bile in health and disease.
Mol. Asp. Med. 2017, 56, 54–65. [CrossRef] [PubMed]
127. Hirano, S.; Masuda, N. Transformation of bile acids by Eubacterium lentum. Appl. Environ. Microbiol. 1981,
42, 912–915. [CrossRef]
128. Hirano, S.; Masuda, N.; Mukai, H.; Hirakawa, K.; Imamura, T. Transformation of bile acids by Bacteroides
fragilis strains isolated from the human intestine (author’s transl). Nihon Saikingaku Zasshi 1979, 34, 403–411.
[CrossRef]
129. Salvioli, G.; Salati, R.; Bondi, M.; Fratalocchi, A.; Sala, B.M.; Gibertini, A. Bile acid transformation by the
intestinal flora and cholesterol saturation in bile. Effects of Streptococcus faecium administration. Digestion
1982, 23, 80–88. [CrossRef]
130. Goodwin, A.C.; Destefano Shields, C.E.; Wu, S.; Huso, D.L.; Wu, X.; Murray-Stewart, T.R.; Hacker-Prietz, A.;
Rabizadeh, S.; Woster, P.M.; Sears, C.L.; et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides
fragilis-induced colon tumorigenesis. Proc. Natl. Acad. Sci. USA 2011, 108, 15354–15359. [CrossRef]
131. Michael, A.J. Polyamine function in archaea and bacteria. J. Biol. Chem. 2018, 293, 18693–18701. [CrossRef]
132. De las Rivas, B.; Marcobal, A.; Carrascosa, A.V.; Munoz, R. PCR detection of foodborne bacteria producing
the biogenic amines histamine, tyramine, putrescine, and cadaverine. J. Food Prot. 2006, 69, 2509–2514.
[CrossRef] [PubMed]
133. Gao, J.; Xu, K.; Liu, H.; Liu, G.; Bai, M.; Peng, C.; Li, T.; Yin, Y. Impact of the Gut Microbiota on Intestinal
Immunity Mediated by Tryptophan Metabolism. Front. Cell. Infect. Microbiol. 2018. [CrossRef] [PubMed]
134. Clausen, M.R.; Mortensen, P.B.; Bendtsen, F. Serum levels of short-chain fatty acids in cirrhosis and hepatic
coma. Hepatology 1991, 14, 1040–1045. [CrossRef] [PubMed]
135. Jakobsdottir, G.; Bjerregaard, J.H.; Skovbjerg, H.; Nyman, M. Fasting serum concentration of short-chain
fatty acids in subjects with microscopic colitis and celiac disease: No difference compared with controls, but
between genders. Scand. J. Gastroenterol. 2013, 48, 696–701. [CrossRef] [PubMed]
136. Ktsoyan, Z.A.; Mkrtchyan, M.S.; Zakharyan, M.K.; Mnatsakanyan, A.A.; Arakelova, K.A.; Gevorgyan, Z.U.;
Sedrakyan, A.M.; Hovhannisyan, A.I.; Arakelyan, A.A.; Aminov, R.I. Systemic Concentrations of Short Chain
Fatty Acids Are Elevated in Salmonellosis and Exacerbation of Familial Mediterranean Fever. Front. Microbiol.
2016, 7, 776. [CrossRef] [PubMed]
Cancers 2020, 12, 1068 23 of 27
137. Pryde, S.E.; Duncan, S.H.; Hold, G.L.; Stewart, C.S.; Flint, H.J. The microbiology of butyrate formation in the
human colon. FEMS Microbiol. Lett. 2002, 217, 133–139. [CrossRef]
138. Ivan, J.; Major, E.; Sipos, A.; Kovacs, K.; Horvath, D.; Tamas, I.; Bay, P.; Dombradi, V.; Lontay, B. The Short-Chain
Fatty Acid Propionate Inhibits Adipogenic Differentiation of Human Chorion-Derived Mesenchymal Stem
Cells Through the Free Fatty Acid Receptor 2. Stem Cells Dev. 2017, 26, 1724–1733. [CrossRef]
139. Fruge, A.D.; Van der Pol, W.; Rogers, L.Q.; Morrow, C.D.; Tsuruta, Y.; Demark-Wahnefried, W. Fecal
Akkermansia muciniphila Is Associated with Body Composition and Microbiota Diversity in Overweight
and Obese Women with Breast Cancer Participating in a Presurgical Weight Loss Trial. J. Acad. Nutr. Diet
2018, 9, 164. [CrossRef]
140. Fellows, R.; Varga-Weisz, P. Chromatin dynamics and histone modifications in intestinal microbiota-host
crosstalk. Mol. Metab. 2019, 27, 30951–30956. [CrossRef]
141. Shimazu, T.; Hirschey, M.D.; Newman, J.; He, W.; Shirakawa, K.; Le Moan, N.; Grueter, C.A.; Lim, H.;
Saunders, L.R.; Stevens, R.D.; et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous
histone deacetylase inhibitor. Science 2013, 339, 211–214. [CrossRef]
142. Menzies, K.J.; Zhang, H.; Katsyuba, E.; Auwerx, J. Protein acetylation in metabolism—Metabolites and
cofactors. Nat. Rev. Endocrinol. 2016, 12, 43–60. [CrossRef] [PubMed]
143. Haase, S.; Haghikia, A.; Wilck, N.; Muller, D.N.; Linker, R.A. Impacts of microbiome metabolites on immune
regulation and autoimmunity. Immunology 2018, 154, 230–238. [CrossRef] [PubMed]
144. Ratajczak, W.; Ryl, A.; Mizerski, A.; Walczakiewicz, K.; Sipak, O.; Laszczynska, M. Immunomodulatory
potential of gut microbiome-derived short-chain fatty acids (SCFAs). Acta Biochim. Pol. 2019, 66, 1–12.
[CrossRef] [PubMed]
145. Kanika, G.; Khan, S.; Jena, G. Sodium Butyrate Ameliorates L-Arginine-Induced Pancreatitis and Associated
Fibrosis in Wistar Rat: Role of Inflammation and Nitrosative Stress. J. Biochem. Mol. Toxicol. 2015, 29, 349–359.
[CrossRef]
146. Bhagat, T.D.; Von Ahrens, D.; Dawlaty, M.; Zou, Y.; Baddour, J.; Achreja, A.; Zhao, H.; Yang, L.; Patel, B.;
Kwak, C.; et al. Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic
cancer-associated fibroblasts. Elife 2019. [CrossRef]
147. Mullins, T.D.; Kern, H.F.; Metzgar, R.S. Ultrastructural differentiation of sodium butyrate-treated human
pancreatic adenocarcinoma cell lines. Pancreas 1991, 6, 578–587. [CrossRef]
148. Pellizzaro, C.; Speranza, A.; Zorzet, S.; Crucil, I.; Sava, G.; Scarlata, I.; Cantoni, S.; Fedeli, M.; Coradini, D.
Inhibition of human pancreatic cell line MIA PaCa2 proliferation by HA-But, a hyaluronic butyric ester: A
preliminary report. Pancreas 2008, 36, e15–e23. [CrossRef]
149. Iwahashi, S.; Ishibashi, H.; Utsunomiya, T.; Morine, Y.; Ochir, T.L.; Hanaoka, J.; Mori, H.; Ikemoto, T.;
Imura, S.; Shimada, M. Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas
cancer and cholangiocarcinoma cell lines. J. Med. Investig. 2011, 58, 106–109. [CrossRef]
150. Norlin, M.; Wikvall, K. Enzymes in the conversion of cholesterol into bile acids. Curr. Mol. Med. 2007, 7,
199–218. [CrossRef]
151. Ridlon, J.M.; Kang, D.J.; Hylemon, P.B. Bile salt biotransformations by human intestinal bacteria. J. Lipid. Res.
2006, 47, 241–259. [CrossRef]
152. Wahlstrom, A.; Sayin, S.I.; Marschall, H.U.; Backhed, F. Intestinal Crosstalk between Bile Acids and Microbiota
and Its Impact on Host Metabolism. Cell Metab. 2016, 24, 41–50. [CrossRef] [PubMed]
153. Midtvedt, T. Microbial bile acid transformation. Am. J. Clin. Nutr. 1974, 27, 1341–1347. [CrossRef] [PubMed]
154. Marshall, W.J.; Lapsley, M.; Day, A. Clinical Chemistry, 8th ed.; Elsevier: Amsterdam, The Netherlands, 2016.
155. Watanabe, M.; Houten, S.M.; Mataki, C.; Christoffolete, M.A.; Kim, B.W.; Sato, H.; Messaddeq, N.; Harney, J.W.;
Ezaki, O.; Kodama, T.; et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone
activation. Nature 2006, 439, 484–489. [CrossRef]
156. MahmoudianDehkordi, S.; Arnold, M.; Nho, K.; Ahmad, S.; Jia, W.; Xie, G.; Louie, G.; Kueider-Paisley, A.;
Moseley, M.A.; Thompson, J.W.; et al. Altered bile acid profile associates with cognitive impairment in
Alzheimer’s disease—An emerging role for gut microbiome. Alzheimers Dement. 2019, 15, 76–92. [CrossRef]
[PubMed]
157. Sarin, S.K.; Pande, A.; Schnabl, B. Microbiome as a therapeutic target in alcohol-related liver disease. J. Hepatol.
2019, 70, 260–272. [CrossRef] [PubMed]
Cancers 2020, 12, 1068 24 of 27
158. McIlvride, S.; Dixon, P.H.; Williamson, C. Bile acids and gestation. Mol. Asp. Med. 2017, 56, 90–100.
[CrossRef] [PubMed]
159. Houten, S.M.; Watanabe, M.; Auwerx, J. Endocrine functions of bile acids. EMBO J. 2006, 25, 1419–1425.
[CrossRef]
160. Tsuei, J.; Chau, T.; Mills, D.; Wan, Y.J. Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer.
Exp. Biol. Med. 2014, 239, 1489–1504. [CrossRef]
161. Rowland, I.R. (Ed.) The Role of the Gut Flora in Toxicity and Cancer; Academic Press: Carshalton, UK, 1988.
162. Goldberg, A.A.; Titorenko, V.I.; Beach, A.; Sanderson, J.T. Bile acids induce apoptosis selectively in
androgen-dependent and -independent prostate cancer cells. PeerJ 2013, 1, e122. [CrossRef]
163. Gafar, A.A.; Draz, H.M.; Goldberg, A.A.; Bashandy, M.A.; Bakry, S.; Khalifa, M.A.; AbuShair, W.; Titorenko, V.I.;
Sanderson, J.T. Lithocholic acid induces endoplasmic reticulum stress, autophagy and mitochondrial
dysfunction in human prostate cancer cells. PeerJ 2016, 4, e2445. [CrossRef]
164. Goldberg, A.A.; Beach, A.; Davies, G.F.; Harkness, T.A.; Leblanc, A.; Titorenko, V.I. Lithocholic bile acid
selectively kills neuroblastoma cells, while sparing normal neuronal cells. Oncotarget 2011, 2, 761–782.
[CrossRef] [PubMed]
165. Blanchet, M.; Brunel, J.M. Bile Acid Derivatives: From Old Molecules to a New Potent Therapeutic Use: An
Overview. Curr. Med. Chem. 2018, 25, 3613–3636. [CrossRef] [PubMed]
166. Phelan, J.P.; Reen, F.J.; Dunphy, N.; O’Connor, R.; O’Gara, F. Bile acids destabilise HIF-1alpha and promote
anti-tumour phenotypes in cancer cell models. BMC Cancer 2016. [CrossRef] [PubMed]
167. Phelan, J.P.; Reen, F.J.; Caparros-Martin, J.A.; O’Connor, R.; O’Gara, F. Rethinking the bile acid/gut microbiome
axis in cancer. Oncotarget 2017, 8, 115736–115747. [CrossRef]
168. Shellman, Z.; Aldhahrani, A.; Verdon, B.; Mather, M.; Paleri, V.; Wilson, J.; Pearson, J.; Ward, C.; Powell, J. Bile
acids: A potential role in the pathogenesis of pharyngeal malignancy. Clin. Otolaryngol. 2017, 42, 969–973.
[CrossRef]
169. Luu, T.H.; Bard, J.M.; Carbonnelle, D.; Chaillou, C.; Huvelin, J.M.; Bobin-Dubigeon, C.; Nazih, H. Lithocholic
bile acid inhibits lipogenesis and induces apoptosis in breast cancer cells. Cell. Oncol. 2018, 41, 13–24.
[CrossRef]
170. Merritt, M.E.; Donaldson, J.R. Effect of bile salts on the DNA and membrane integrity of enteric bacteria.
J. Med. Microbiol. 2009, 58, 1533–1541. [CrossRef]
171. Garcia-Quintanilla, M.; Prieto, A.I.; Barnes, L.; Ramos-Morales, F.; Casadesus, J. Bile-induced curing of the
virulence plasmid in Salmonella enterica serovar Typhimurium. J. Bacteriol. 2006, 188, 7963–7965. [CrossRef]
172. Prieto, A.I.; Ramos-Morales, F.; Casadesus, J. Repair of DNA damage induced by bile salts in Salmonella
enterica. Genetics 2006, 174, 575–584. [CrossRef]
173. Prieto, A.I.; Ramos-Morales, F.; Casadesus, J. Bile-induced DNA damage in Salmonella enterica. Genetics
2004, 168, 1787–1794. [CrossRef]
174. Kandell, R.L.; Bernstein, C. Bile salt/acid induction of DNA damage in bacterial and mammalian cells:
Implications for colon cancer. Nutr. Cancer 1991, 16, 227–238. [CrossRef] [PubMed]
175. Schaffler, H.; Breitruck, A. Clostridium difficile—From Colonization to Infection. Front. Microbiol. 2018, 9.
[CrossRef] [PubMed]
176. Sorg, J.A.; Sonenshein, A.L. Inhibiting the initiation of Clostridium difficile spore germination using analogs
of chenodeoxycholic acid, a bile acid. J. Bacteriol. 2010, 192, 4983–4990. [CrossRef] [PubMed]
177. Slocum, M.M.; Sittig, K.M.; Specian, R.D.; Deitch, E.A. Absence of intestinal bile promotes bacterial
translocation. Am. Surg. 1992, 58, 305–310.
178. Rees, D.O.; Crick, P.J.; Jenkins, G.J.; Wang, Y.; Griffiths, W.J.; Brown, T.H.; Al-Sarireh, B. Comparison of
the composition of bile acids in bile of patients with adenocarcinoma of the pancreas and benign disease.
J. Steroid. Biochem. Mol. Biol. 2017, 174, 290–295. [CrossRef]
179. Feng, H.Y.; Chen, Y.C. Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new
perspective. World J. Gastroenterol. 2016, 22, 7463–7477. [CrossRef]
180. Gandhi, D.; Ojili, V.; Nepal, P.; Nagar, A.; Hernandez-Delima, F.J.; Bajaj, D.; Choudhary, G.; Gupta, N.;
Sharma, P. A pictorial review of gall stones and its associated complications. Clin. Imaging 2019, 60, 228–236.
[CrossRef]
181. Fu, H.; Li, Y.; Bai, G.; Yin, R.; Yin, C.; Shi, W.; Zhang, L.; Li, R.; Zhao, R. Persistent cholestasis resulting from
duodenal papillary carcinoma in an adolescent male: A case report. Medicine 2019, 98, e15708. [CrossRef]
Cancers 2020, 12, 1068 25 of 27
182. Thomas, R.M.; Jobin, C. Microbiota in pancreatic health and disease: The next frontier in microbiome research.
Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 53–64. [CrossRef]
183. Bernstein, C.; Bernstein, H.; Payne, C.M.; Dvorak, K.; Garewal, H. Field defects in progression to
gastrointestinal tract cancers. Cancer Lett. 2008, 260, 1–10. [CrossRef]
184. Tucker, O.N.; Dannenberg, A.J.; Yang, E.Y.; Fahey Iii, T.J. Bile acids induce cyclooxygenase-2 expression in
human pancreatic cancer cell lines. Carcinogenesis 2004, 25, 419–423. [CrossRef] [PubMed]
185. Adachi, T.; Tajima, Y.; Kuroki, T.; Mishima, T.; Kitasato, A.; Fukuda, K.; Tsutsumi, R.; Kanematsu, T. Bile-reflux
into the pancreatic ducts is associated with the development of intraductal papillary carcinoma in hamsters.
J. Surg. Res. 2006, 136, 106–111. [CrossRef] [PubMed]
186. Ura, H.; Makino, T.; Ito, S.; Tsutsumi, M.; Kinugasa, T.; Kamano, T.; Ichimiya, H.; Konishi, Y. Combined effects
of cholecystectomy and lithocholic acid on pancreatic carcinogenesis of N-nitrosobis(2-hydroxypropyl)amine
in Syrian golden hamsters. Cancer Res. 1986, 46, 4782–4786. [PubMed]
187. Nagathihalli, N.S.; Beesetty, Y.; Lee, W.; Washington, M.K.; Chen, X.; Lockhart, A.C.; Merchant, N.B. Novel
mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: Impact on
gastrointestinal cancers driven by secondary bile acids. Cancer Res. 2014, 74, 2062–2072. [CrossRef] [PubMed]
188. Kim, Y.J.; Jeong, S.H.; Kim, E.K.; Kim, E.J.; Cho, J.H. Ursodeoxycholic acid suppresses epithelial-mesenchymal
transition and cancer stem cell formation by reducing the levels of peroxiredoxin II and reactive oxygen
species in pancreatic cancer cells. Oncol. Rep. 2017, 38, 3632–3638. [CrossRef] [PubMed]
189. Hummel, D.; Aggarwal, A.; Borka, K.; Bajna, E.; Kallay, E.; Horvath, H.C. The vitamin D system is deregulated
in pancreatic diseases. J. Steroid. Biochem. Mol. Biol. 2014, 144, 402–409. [CrossRef]
190. Chen, X.-L.; Xie, K.-X.; Yang, Z.-L.; Yuan, L.-W. Expression of FXR and HRG and their clinicopathological
significance in benign and malignant pancreatic lesions. Int. J. Clin. Exp. Pathol. 2019, 12, 2111–2120.
191. Koutsounas, I.; Giaginis, C.; Alexandrou, P.; Zizi-Serbetzoglou, A.; Patsouris, E.; Kouraklis, G.; Theocharis, S.
Pregnane X Receptor Expression in Human Pancreatic Adenocarcinoma: Associations With Clinicopathologic
Parameters, Tumor Proliferative Capacity, Patients’ Survival, and Retinoid X Receptor Expression. Pancreas
2015, 44, 1134–1140. [CrossRef]
192. Kashiwagi, K.; Yanagida, M.; Matsui, D.; Tanaka, M.; Sugimoto, K.; Chen, H.; Ichikawa-Tomikawa, N.;
Marubashi, S.; Suzuki, H.; Chiba, H. Expression of liver X receptors in normal and refractory carcinoma
tissues of the human lung and pancreas. Histol. Histopathol. 2018, 33, 497–505.
193. Saraswat, M.; Joenvaara, S.; Seppanen, H.; Mustonen, H.; Haglund, C.; Renkonen, R. Comparative proteomic
profiling of the serum differentiates pancreatic cancer from chronic pancreatitis. Cancer Med. 2017, 6,
1738–1751. [CrossRef]
194. Candelaria, N.R.; Addanki, S.; Zheng, J.; Nguyen-Vu, T.; Karaboga, H.; Dey, P.; Gabbi, C.; Vedin, L.-L.; Liu, K.;
Wu, W.; et al. Antiproliferative effects and mechanisms of liver X receptor ligands in pancreatic ductal
adenocarcinoma cells. PLoS ONE 2014, 9, e106289. [CrossRef] [PubMed]
195. Massaro, C.; Thomas, J.; Phanstiel Iv, O. Investigation of Polyamine Metabolism and Homeostasis in
Pancreatic Cancers. Med. Sci. 2017, 5. [CrossRef]
196. Gitto, S.B.; Pandey, V.; Oyer, J.L.; Copik, A.J.; Hogan, F.C.; Phanstiel, O.T.; Altomare, D.A.
Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine
Resistant Pancreatic Cancer. Mol. Pharm. 2018, 15, 369–376. [CrossRef] [PubMed]
197. Mohammed, A.; Janakiram, N.B.; Madka, V.; Ritchie, R.L.; Brewer, M.; Biddick, L.; Patlolla, J.M.; Sadeghi, M.;
Lightfoot, S.; Steele, V.E.; et al. Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating
ornithine decarboxylase signaling. Cancer Prev. Res. 2014, 7, 1198–1209. [CrossRef]
198. Saydjari, R.; Alexander, R.W.; Barranco, S.C.; Townsend, C.M., Jr.; Thompson, J.C. The effects of
2-deoxy-D-glucose and alpha-difluoromethylornithine on the growth of pancreatic cancer in vivo. Pancreas
1989, 4, 38–43. [CrossRef]
199. Chang, B.K.; Gutman, R.; Black, O., Jr. Combined effects of alpha-difluoromethylornithine and doxorubicin
against pancreatic cancer cell lines in culture. Pancreas 1986, 1, 49–54. [CrossRef]
200. Chang, B.K.; Bergeron, R.J.; Porter, C.W.; Liang, Y. Antitumor effects of N-alkylated polyamine analogues in
human pancreatic adenocarcinoma models. Cancer Chemother. Pharmacol. 1992, 30, 179–182. [CrossRef]
201. Wortham, B.W.; Patel, C.N.; Oliveira, M.A. Polyamines in bacteria: Pleiotropic effects yet specific mechanisms.
Adv. Exp. Med. Biol. 2007, 603, 106–115. [CrossRef]
Cancers 2020, 12, 1068 26 of 27
202. Miller-Fleming, L.; Olin-Sandoval, V.; Campbell, K.; Ralser, M. Remaining Mysteries of Molecular Biology:
The Role of Polyamines in the Cell. J. Mol. Biol. 2015, 427, 3389–3406. [CrossRef]
203. Seiler, N. Catabolism of polyamines. Amino Acids 2004, 26, 217–233. [CrossRef]
204. Lu, Y.-C.; Yeh, W.-C.; Ohashi, P.S. LPS/TLR4 signal transduction pathway. Cytokine 2008, 42, 145–151.
[CrossRef] [PubMed]
205. Bertani, B.; Ruiz, N. Function and Biogenesis of Lipopolysaccharides. EcoSal Plus 2018, 8. [CrossRef]
[PubMed]
206. Yokoyama, M.T.; Carlson, J.R. Microbial metabolites of tryptophan in the intestinal tract with special reference
to skatole. Am. J. Clin. Nutr. 1979, 32, 173–178. [CrossRef] [PubMed]
207. Wikoff, W.R.; Anfora, A.T.; Liu, J.; Schultz, P.G.; Lesley, S.A.; Peters, E.C.; Siuzdak, G. Metabolomics analysis
reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. USA 2009, 106,
3698–3703. [CrossRef] [PubMed]
208. Browne, C.A.; Clarke, G.; Dinan, T.G.; Cryan, J.F. An effective dietary method for chronic tryptophan
depletion in two mouse strains illuminates a role for 5-HT in nesting behaviour. Neuropharmacology 2012, 62,
1903–1915. [CrossRef] [PubMed]
209. El Aidy, S.; Kunze, W.; Bienenstock, J.; Kleerebezem, M. The microbiota and the gut-brain axis: Insights
from the temporal and spatial mucosal alterations during colonisation of the germfree mouse intestine.
Benef. Microbes. 2012, 3, 251–259. [CrossRef]
210. Mardinoglu, A.; Shoaie, S.; Bergentall, M.; Ghaffari, P.; Zhang, C.; Larsson, E.; Backhed, F.; Nielsen, J. The gut
microbiota modulates host amino acid and glutathione metabolism in mice. Mol. Syst. Biol. 2015, 11, 834.
[CrossRef]
211. Roager, H.M.; Licht, T.R. Microbial tryptophan catabolites in health and disease. Nat. Commun. 2018, 9, 3294.
[CrossRef]
212. DeMoss, R.D.; Moser, K. Tryptophanase in diverse bacterial species. J. Bacteriol. 1969, 98, 167–171. [CrossRef]
213. Ma, Q.; Zhang, X.; Qu, Y. Biodegradation and Biotransformation of Indole: Advances and Perspectives.
Front. Microbiol. 2018, 9, 2625. [CrossRef]
214. Zelante, T.; Iannitti, R.G.; Cunha, C.; De Luca, A.; Giovannini, G.; Pieraccini, G.; Zecchi, R.; D’Angelo, C.;
Massi-Benedetti, C.; Fallarino, F.; et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon
receptor and balance mucosal reactivity via interleukin-22. Immunity 2013, 39, 372–385. [CrossRef] [PubMed]
215. Venkatesh, M.; Mukherjee, S.; Wang, H.; Li, H.; Sun, K.; Benechet, A.P.; Qiu, Z.; Maher, L.; Redinbo, M.R.;
Phillips, R.S.; et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic
sensor PXR and Toll-like receptor 4. Immunity 2014, 41, 296–310. [CrossRef] [PubMed]
216. Lamas, B.; Richard, M.L.; Leducq, V.; Pham, H.P.; Michel, M.L.; Da Costa, G.; Bridonneau, C.; Jegou, S.;
Hoffmann, T.W.; Natividad, J.M.; et al. CARD9 impacts colitis by altering gut microbiota metabolism of
tryptophan into aryl hydrocarbon receptor ligands. Nat. Med. 2016, 22, 598–605. [CrossRef] [PubMed]
217. Kim, C.H. Immune regulation by microbiome metabolites. Immunology 2018, 154, 220–229. [CrossRef]
218. Sonner, J.K.; Keil, M.; Falk-Paulsen, M.; Mishra, N.; Rehman, A.; Kramer, M.; Deumelandt, K.; Rowe, J.;
Sanghvi, K.; Wolf, L.; et al. Dietary tryptophan links encephalogenicity of autoreactive T cells with gut
microbial ecology. Nat. Commun. 2019, 10, 4877. [CrossRef]
219. Shi, L.Z.; Faith, N.G.; Nakayama, Y.; Suresh, M.; Steinberg, H.; Czuprynski, C.J. The aryl hydrocarbon
receptor is required for optimal resistance to Listeria monocytogenes infection in mice. J. Immunol. 2007, 179,
6952–6962. [CrossRef]
220. Qiu, J.; Heller, J.J.; Guo, X.; Chen, Z.-m.E.; Fish, K.; Fu, Y.-X.; Zhou, L. The aryl hydrocarbon receptor regulates
gut immunity through modulation of innate lymphoid cells. Immunity 2012, 36, 92–104. [CrossRef]
221. Zhang, L.; Nichols, R.G.; Patterson, A.D. The aryl hydrocarbon receptor as a moderator of host-microbiota
communication. Curr. Opin. Toxicol. 2017, 2, 30–35. [CrossRef]
222. Jin, U.H.; Kim, S.B.; Safe, S. Omeprazole Inhibits Pancreatic Cancer Cell Invasion through a Nongenomic
Aryl Hydrocarbon Receptor Pathway. Chem. Res. Toxicol. 2015, 28, 907–918. [CrossRef]
223. Ansari, D.; Toren, W.; Zhou, Q.; Hu, D.; Andersson, R. Proteomic and genomic profiling of pancreatic cancer.
Cell Biol. Toxicol. 2019, 35, 333–343. [CrossRef]
224. Brown, J.M.; Hazen, S.L. Targeting of microbe-derived metabolites to improve human health: The next
frontier for drug discovery. J. Biol. Chem. 2017, 292, 8560–8568. [CrossRef] [PubMed]
Cancers 2020, 12, 1068 27 of 27
225. Descamps, H.C.; Herrmann, B.; Wiredu, D.; Thaiss, C.A. The path toward using microbial metabolites as
therapies. EBioMedicine 2019, 44, 747–754. [CrossRef] [PubMed]
226. Szanto, M.; Dozsa, A.; Antal, D.; Szabo, K.; Kemeny, L.; Bai, P. Targeting the gut-skin axis—Probiotics as new
tools for skin disorder management? Exp. Dermatol. 2019. [CrossRef] [PubMed]
227. Velicer, C.M.; Heckbert, S.R.; Lampe, J.W.; Potter, J.D.; Robertson, C.A.; Taplin, S.H. Antibiotic use in relation
to the risk of breast cancer. JAMA 2004, 291, 827–835. [CrossRef] [PubMed]
228. Varian, B.J.; Goureshetti, S.; Poutahidis, T.; Lakritz, J.R.; Levkovich, T.; Kwok, C.; Teliousis, K.; Ibrahim, Y.M.;
Mirabal, S.; Erdman, S.E. Beneficial bacteria inhibit cachexia. Oncotarget 2016, 7, 11803–11816. [CrossRef]
229. Mills, S.; Stanton, C.; Lane, J.A.; Smith, G.J.; Ross, R.P. Precision Nutrition and the Microbiome, Part I: Current
State of the Science. Nutrients 2019, 11, 923. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
